Document:

CONFIDENTIAL
    TREATMENT REQUESTED	 

 

 

 

 

 

 

 

PATENT
RIGHTS ASSIGNMENT AGREEMENT

 

 

between

 

 

Inventergy,
Inc. 

 

 

and

 

 

 Huawei
Technologies Co., Ltd.

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 1 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

PATENT RIGHTS ASSIGNMENT AGREEMENT

 

This PATENT RIGHTS
ASSIGNMENT AGREEMENT (“Agreement”) is entered into by and between Huawei Technologies Co., Ltd., a Chinese Corporation,
having offices at Administration Building Huawei Technologies Co., Ltd. Bantian Longgang District, Shenzhen 518129, P. R. China
(“Assignor”) , and Inventergy, Inc., a Delaware corporation, having offices at 19925 Stevens Creek Boulevard, Suite
100, Cupertino, California, 95014 United States of America (“Assignee”) (Assignee and Assignor each a “Party”
and together the “Parties”).

 

WHEREAS Assignor owns
certain rights, title and interest in and to the Transferred Patents (as defined below) and Assignor wishes to sell its entire
rights, title and interest in and to the Transferred Patents to Assignee;

 

WHEREAS Assignor wishes
to sell Assignor’s entire rights, title and interest in and to the Transferred Patents and the causes of action to sue for
infringement thereof and other enforcement rights;

 

WHEREAS Assignee wishes
to purchase Assignor’s entire rights, title and interest in and to the Transferred Patents;

 

and

 

WHEREAS the Parties
wish to share the net revenue arising from the commercialization of the Transferred Patents.

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

1Definitions

 

1.1“Affiliate”
means, with respect to a Party, any other entity directly or indirectly controlling, controlled by or under common control with
such Party. For purposes of this definition, the term “control” (including the correlative terms “controlled
by” and “under common control with”), as used with respect to any entity, means the possession, directly or indirectly,
more than 50% of the outstanding voting shares or securities (or other ownership interest as the case may be in a partnership,
joint venture or unincorporated association) or the possession of the power to direct or cause the direction of the overall management
policies of such entity, whether through the ownership of voting securities or by contract or otherwise.

 

1.2“Assignment
Agreement” means a written assignment of ownership expressly directed to a patent and/or patent application of a Transferred
Patent Right by the inventor(s) and/or prior owners of a patentable invention disclosed in such patent or patent application.

 

 

 

 

 

 

 

 

*Please note parts
of this Agreement are designated with an asterisk which indicates that material has been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 2 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

1.3“Challenge
Process” means an opposition, ex parte, inter-partes or Post Grant Review, or similar administrative challenge
against any patent in any jurisdiction.

 

 

1.4Common Interest
Agreement” means an agreement, in the form set forth on Exhibit E, setting for the continuing terms under which Assignor
and Assignee will protect certain information relating to the Transferred Patents under applicable common interest privileges.

 

1.5
“Docket”
means Assignor’s or its agents’ list or other means of tracking information relating to the prosecution or maintenance
of the Transferred Patents throughout the patent covered territories, including, without limitation, the names, addresses, email
addresses, and phone numbers of prosecution counsel and agents, and information relating to deadlines, payments, and filings, which
list or other means of tracking information, to the extent they exist and are reasonably available to Assignor, is current as of
the Effective Date. 

 

1.6“Due
Date” means at latest date on which a payment can be made or an action taken without incurring a penalty, surcharge or
other additional payment.

 

1.7“Effective
Date” means the date set forth as the Effective Date on the signature page of this Agreement.

 

1.8“Escrow
Agent” means an Escrow Agent appointed and approved by both Assignor and Assignee to receive documents pursuant to this
Agreement, as agreed to by the Escrow Agreement attached as Exhibit F.

 

1.9“Executed
Assignments” means executed and witnessed Assignment(s) of Patent Rights in Exhibit B, each as signed by a duly authorized
representative of Assignor.

 

1.10
“Knowledge” with respect to a Party means the actual
knowledge of such Party’s current officers and current employees of such Party who has been directly responsible for or directly
involved in the patent prosecution and/or licensing (other than with respect to agreements relating to the sales of products in
the ordinary course of business) of the Transferred Patents. 

 

1.11“Transferred
Patents” means (subject to Section 4.5) all patents (“Listed Patents”) and patent applications (“Transferred
Patent Applications”) of each Patent Family listed in Exhibit A hereto. “Patent Family” includes all such Listed
Patents and/or Transferred Patent Applications, and any other patent(s) and/or patent application(s) that either claim priority
to such Listed Patents and/or Transferred Patent Applications, or to which such Listed Patents and/or Transferred Patent Applications
claim priority, whether pending, granted, lapsed or otherwise expired.

 

1.12“Prosecution
History Files” means all files, documents and tangible things that are in the central repository in which Assignor stores
substantially all of the corporate files relating to its patents and patent applications and maintained by Assignor or its outside
prosecution counsel, as those terms have been interpreted pursuant to rules and laws governing the production of documents and
things, constituting, comprising or relating to the prosecution, maintenance, filing, issuance, registration, assertion of the
Patents.

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 3 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

1.13“Net
Revenue” means all income, whether in cash or any other form of benefits to Assignee and any of its assigns, successor-in-interests
or exclusive licensees, derived and actually received by Assignee or its assigns, successor-in-interests or exclusive licensees
from licensing, revenue sharing, selling, or other monetization of the Transferred Patents, less

 

(a) any reimbursement
to its licensees due to overpayments from such licensees to Assignee and

 

(b) all accrued
third party litigation related expenses reasonably directly related and attributable to the assertion, enforcement or other related
activities for the Transferred Patents, only to the extent such fees and expenses can be reasonably proved by written documentation
provided to Assignor, including fees for (i) third party technical experts as litigation consultants and expert witnesses, litigation
firms and damages experts, (ii) litigation related document preparation costs, and (ii) any court related costs or fees.

 

For the avoidance of
doubt, Net Revenue does not encompass any receipts by Assignee due to general corporate financing, whether equity or debt, or money
or other value received as part of changes of control, mergers or acquisitions of substantially all the assets of Inventergy, its
successors or assigns, or similar general corporate transactions.

 

2Payment and
revenue sharing

 

2.1Purchase
Payment. Assignee shall pay to Assignor the initial Purchase Payment amount of * US Dollars ($*), a) Four Million US Dollars
($4,000,000) (“First Payment”) to be paid within 10 business days following Assignee’s receipt of the written
notice from the Escrow Agent, no portion of which shall be refundable;
b) Assignee shall pay Assignor the remaining Purchase Payment amount of * US Dollars ($*) (“Second Payment”) when Assignee
has received * US Dollars ($*) in Net Revenue, no portion of which
shall be refundable. The aforesaid subsection b) payment shall be due within thirty (30) calendar days following the last day of
the specific quarter in which the Net Revenue comes to * US Dollars ($*).

 

2.2The payments
specified in Section 2.1 hereof shall be made to Assignor in U.S. Dollars by wire transfer to the following account:

 

Huawei
Technologies Co., Ltd.,

Account
Name: *

Account
Number: *

Bank Name:
*

Bank Swift
Code: *

 

2.3If Assignor
does not receive the First Payment set forth in this Section 2.1 a) 15 business days after Assignor has received the written notice
from the Escrow Agent, Assignor shall have the right to void this Agreement ab initio upon written notice to Assignee. Upon termination,
Assignee and the Escrow Agent will return all documents delivered to Assignee and/or the Escrow Agent under Section 4 to Assignor,
including in particular the Executed Assignment(s) and all such Executed Assignments are void ab initio. The provisions of Sections
7 and 8 will survive any termination.

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 4 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

2.4Shared Revenue.
In addition to the Purchase Payment of Section 2.1, Assignee shall pay Assignor Shared Revenue of * percent (*%) (“Net Revenue
Percentage”) of Net Revenue. Beginning with the first calendar quarter following the Effective Date of this Agreement, and
continuing each quarter thereafter, Assignee shall provide Assignor with a statement, accompanied with reasonable sufficient supporting
documentation for the defined revenue and expense calculations of Section 1.12, of the amount of Net Revenue received during the
immediately preceding calendar quarter along with the Shared Revenue payment due, if any. Such statement and Shared Revenue payments
shall be due within thirty (30) calendar days following the last day of each quarter. If Huawei * any of its * as set forth in
Section *, then for each such *, the * will be reduced for * (or earlier if that particular * ends earlier (pursuant to particular
provisions of Section *)) in the following fashion: if only * is currently in effect during any period, the * will be * at Year
*, another * at Year *, and yet another * at Year *, the * will be reduced to *% from the beginning of year * to the beginning
of year *; to *% between the start of Year * to Year *; *% between Year * and the start of Year *; back up to *% between the start
of Year * and the start of Year * (because the next * is then the primary existing * after the previous * ends and therefore reduces
the * by *% rather than the previous *%); increases to *% between the start of Year * and Year * (the final * now being primary),
and thereafter back * to the *%.

 

(a) For any
potential transaction in which Net Revenue may be realized and for which the transaction involves a mixture of Transferred Patents
and other patents owned by Assignee, the Parties agree to negotiate in good faith for the appropriate apportionment of the revenue
as well as the expenses per Section 1.12 prior to concluding such a transaction

 

(b)
For any * of any of the Transferred Patents by Assignee, Assignor is granted * for such action, except in cases of (i) * and (ii)
*).

 

2.5Taxes. All payments
to be made by the Assignee to the Assignor under this Section 2 shall be made without any set-off, counterclaim, withholding or
deduction, be it tax-related or otherwise, unless specifically required by any applicable laws and/or regulations as reasonably
determined by Parties.  In the event that a withholding tax or tax deduction is required, the Assignee can make the payment
to the Assignor net of the withholding tax or tax deduction, subject to the following requirements under this Section.

 

(a) Both the
Assignee and the Assignor shall use commercially reasonable efforts to do all such things and acts and to sign all such documents
as will enable them to take advantage of any benefits under the applicable treaties or agreements between or otherwise recognized
by their respective jurisdiction.

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 5 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

(b) The Assignee
shall supply to the Assignor evidence to the reasonable satisfaction of the Assignor that the Assignee has accounted to the appropriate
governmental authorities for the tax withheld or deducted, and shall provide all such assistance as may be requested by the Assignor
in recovering, or otherwise obtaining any benefits on account of, the tax withheld or deducted. In particular, the Assignee shall
be responsible for obtaining a tax clearance certificate from appropriate governmental tax authorities and provide it to the Assignor
within 60 days after such taxes shall become due and payable.

 

(c) If the
Assignee intends to make a payment to the Assignor in accordance with Section 2.1(b)(“Second Payment”) and 2.4(“Shared
Revenue”), the Assignee will first notify Assignor of such intent and Assignor will notify Assignee within ten (10) business
days of whether the Assignee should or should not withhold or deduct any taxes. Assignee is deemed by this Agreement to have the
intent not to pay any withholding tax for the $4,000,000 First Payment set forth in Section 2.1(a), as appropriate notice to Assignor
for this Section’s purposes. If the Assignee, based on a foregoing notice of Assignor, makes a payment to Assignor without
withholding or deducting any taxes and a subsequent audit or other examination identifies that a withholding or deduction should
have been made from the payment, the Assignor shall be solely and exclusively liable to bear and settle with the appropriate governmental
authorities the taxes not withheld or deducted, along with any interest, penalties and other charges associated therewith the taxes
and determined based upon the taxes.

 

2.6Audit of
Records.  No more than once each calendar year and upon reasonable advance written notice, Assignor may have an independent
auditor audit the applicable records, at Assignor’s request and expense, to verify the accuracy of the calculations of shared
revenue due to Assignor under this Agreement. All such records shall be treated as confidential information by the independent
auditor and shall not be disclosed to Assignor except insofar as necessary to verify to Assignor the accuracy of Assignee’s
payments to Assignor. Any payment adjustments (whether due to under- or over-payments) shall be incorporated with the next quarterly
payment under this Agreement. Should any payment be underpaid by 5% or more, without reasonable explanation, then Assignee shall
pay the reasonable expense of such audit, if any, along with a late payment fee of interest on the under-payment amount at an annual
interest rate of * (*%) or the maximum interest rate permitted by law, whichever is lesser, paid with the next quarterly
payment due under this Agreement. Assignee shall preserve and maintain all such books and records required for audit for a period
of five (5) years after the calendar quarter for which the books and records apply. 

 

3Assignment
and License back

 

3.1Patent Assignment.
Effective as of the Effective Date, but perfected at Closing, including Assignor’s receipt of First Payment set forth in
Section 2.1a) (“Assignment Date”), Assignor hereby sells, assigns, and transfers to Assignee, subject to encumbrances
attendant to the Transferred Patents including which has been specifically set forth on Exhibit C, its entire right, title and
interest in and to all of the Transferred Patents. Assignor understands and acknowledges that, if any of the Transferred Patents
are assigned to Assignor’s Affiliates, Assignor may be required prior to the Closing to perform certain actions to establish
that Assignor is the assignee and to record such assignments.

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 6 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

3.2Assignment
of Additional Rights. As of Assignment Date, Assignor hereby also sells, assigns, transfers, and conveys to Assignee all right,
title and interest in and to all:

 

(a)any and all continuations,
divisionals, reissues, reexaminations, or other similar refiling or additional filing of a patent application for claims based
upon embodiments contained in the specifications of any of the Transferred Patents

 

(b)rights
to apply in any or all countries of the world for patents, certificates of invention, utility models, industrial design protections,
design patent protections, or other governmental grants or issuances of any type related to any of the Transferred Patents;

 

(c)causes
of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on
account of, any of the Transferred Patents and/or the rights described in subparagraph 3.2(b), including, without limitation, all
causes of action and other enforcement rights for (i) past, present and future damages, (ii) injunctive relief, and (iii) any
other remedies of any kind for past, current and future infringement; and

 

(d)rights
to collect past, present and future royalties or other payments under or on account of any of the Transferred Patents and/or any
of the foregoing, except to the extent such royalties arise under or are otherwise associated with any of the pre-existing encumbrances.

  

3.3License Back.
Effective as of the Assignment Date, Assignee hereby grants to Assignor and its current and future Affiliates, under the Transferred
Patents, a royalty-free, fully-paid up, perpetual, irrevocable, worldwide, non-exclusive, non-sublicensable (except as expressly
set forth in this Agreement), * (*) right and license to practice any methods and to make, have made, use, distribute, lease, sell,
offer for sale, license, import, export, manufacture, develop, design, and/or otherwise dispose of any products or services, regardless
of using any trademark or trade name of Assignor, its current and future Affiliates, or any third party (“Assignor Products”)
For further clarity, the license under this Section shall cover * or * activities that Assignor may * to * which are *, *, and/or
* by such *. This license shall extend to *. “*” means a * of a * with a *, only: (i) if the * would,
absent the license granted in this Agreement, constitute infringement (whether direct, contributory or induced) of a claim within
an Transferred Patent; and (ii) if the combination of the third party product with the Assignor Product infringes a claim of an
Transferred Patent that would not be infringed by the third party product absent such combination (“*”).
Such license to * shall extend only to the portion or functionality of the * which is enabled by the *. No license is granted for
any * on a * (i.e., *), and the * hereunder to * shall extend only to *.

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 7 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

3.4As of the Assignment
Date, Assignee agrees not to assert, claim for potential infringement or file suit in any court of law or the International Trade
Commission, or permit any of its Affiliates to assert, claim for potential infringement or file suit, in any case with respect
to the Transferred patents against (i) each direct or indirect authorized distributor, reseller, OEM, supplier, agent, end-users,
or customers of Assignor or its Affiliates, with respect to making, using, importing and/or selling Assignor Products, or (ii)
Assignor or its Affiliates.

 

(a) As of the Assignment Date
and for a period of two calendar years, Assignee agrees not to assert, claim for potential infringement or file suit in any court
of law or the International Trade Commission, or permit any of its Affiliates to assert, claim for potential infringement or file
suit, in any case with respect to the any patent that is acquired, owned
or for which the Assignee or its Affiliates have a right to license, against Assignor or its Affiliates.

 

3.5The provisions
of Sections 3.3 and 3.4 (not including 3.4(a)) includes the right to grant, without notice or accounting and with any required
consents hereby deemed granted by Assignee, similar rights and provisions of the same or lesser scope to (i) * to which, on or
after the Effective Date, Assignor *, provided however, any sublicense granted pursuant to this Section 3.5(i) shall be no more
broad than necessary * and any *, *, *, * or * of those *, or (ii) to * which * or * is subsequently *, provided however, any sublicense
granted pursuant to this Section 3.5(ii) shall be no more broad than necessary to *, and any *, *, *, * or * of those products
or services.

 

3.6As of the Assignment
Date and subject to the conditions of Section 3.6 below, Assignee covenants specifically to Assignor not to assert, claim for potential
infringement or file suit in any court of law or the International Trade Commission based on, or permit any of its Affiliates to
file suit based on, any claim of the Transferred Patents * listed in Exhibit G (“*”). The promise and covenant of this
Section 3.6 is personal between Assignee and Assignor. The * in Exhibit G are specifically *, and shall not *.

 

3.7As of the Assignment
Date, Assignee and/or any of its Affiliates may enter into *, *, * or * or the * based on * against any * listed in Exhibit H (“*”).
Assignor has the right, at any time after the Effective Date, to add up to * additional *, * or * (but not * which *) to Exhibit
H (“*”). At Assignor’s election, Assignor may request that Assignee covenant to Assignor that if any * for up
to * (*) * (“*”) (such * to Assignee termed a “*”). Assignor has the right, which can be used repeatedly
for * times, to conduct a further * (such further * shall not be treated as a repeat for the *, and shall not constitute another
*. By way of explanation, and for avoidance of doubt, should Assignor elects to practice a * on * at Year *, subsequently practice
a further request on an *, which is covered in Exhibit H, at Year *, such further request shall be deemed as a repeat but shall
not constitute another * or cause any further * pursuant to Section 2.5.). Before such *, Assignor agrees to cooperate with Assignee
and such *. As for any of the * or the * indicated * listed in List A of Exhibit H, the * shall be made within * days of the *.
Such * shall terminate with respect to any such *, should such Entity *, *, or *, or *, *, except if i) the Additional Entity *,
*, *, *, or *, *, or * within * days * or ii) if beyond the * period after * the * and/or in the event that the aforesaid *, the
* agrees with Assignee to * and *. Assignee agrees that, except as expressly stated under this Section, it shall comply with the
Assignor’s *. The promises and covenants of this Section 3.7 are personal between Assignee and Assignor. The * in Exhibit
H are specifically not *, and shall not themselves have the power to enforce this * in at *, * or in *. After the Effective Date,
Assignee will provide reasonable notification of any *, *, * or * on any of the Transferred Patents owned by Assignee, by *, and
also provide notification on or before the * by Assignee of any * based on any of the Transferred Patents. Upon receipt of such
notification, Assignor *, if necessary, as soon as possible.

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 8 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

3.8If after the
Effective Date, any of the * listed in Exhibit G and H * a *, the * to Assignor under Sections 3.6 and 3.7 shall not apply to this
*.

 

3.9Option Right.
For one calendar year after the Closing date, Assignee has the option to acquire United States Patent 7,796,622 together with all
related patent family members, (as defined in a similar fashion to each of the patent families in the Transferred Patents) (collectively,
“the ’622 Patent Family).

 

 

4Closing

 

4.1Transmittals
at Execution. Within ten (10) business days following the Effective Date, Assignor will deliver the following items:

 

(a) To Assignee’s Representatives:
a transmitted copy of this Agreement and promptly thereafter delivered two (2) executed originals of this Agreement to Assignee’s
representatives.

 

(b) To the Escrow Agent: one
original Executed Assignment(s) as provided in Exhibit B.

 

4.2Transmittals.
At or before Closing, Assignor will send to Assignee electronic copies of Prosecution History Files for each Transferred Patent
(including pending applications). And within sixty (60) calendar days following the Closing Date, Assignor will deliver to Assignee,
or its legal counsel, the items, to the extent they exist and are reasonably available to Assignor identified on Exhibit
D (the “Deliverables”).

 

4.3Closing.
The closing of the sale of the Transferred Patents hereunder will occur when all conditions set forth in Section 4.4 have been
satisfied or waived and the payment set forth in Section 2.1a) is made (the “Closing”).

 

4.4Closing Conditions.
The following are conditions precedent to Assignee’s obligation to make the payment in paragraph 4.4.

 

(a)Signature
by Assignor. Assignor timely executed this Agreement and delivered a Transmitted Copy of this Agreement to Assignee’s
representatives by not later than May 15, 2013 at 6:00 p.m., Pacific Standard time and promptly delivered two (2) executed originals
of this Agreement to Assignee’s representatives, as well as an executed copy of this Agreement to the Escrow Agent.

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 9 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

(b)Representations
and Warranties True. Assignee is satisfied that, as of the Closing Date, the representations and warranties of Assignor contained
in Section 6 are true and correct.

 

(c)Delivery of Executed
Assignments. Assignor caused the Executed Assignments to be delivered to the Escrow Agent.

 

4.5Payment and
Release. Payment of the First Payment to the account set forth in Sections 2.1, 2.2 shall fully satisfy all initial payment
obligations under this Agreement to Assignor. Upon receipt of the executed copy of this Agreement as well as the original Executed
Assignment(s), Escrow Agent shall immediately give Parties a written notice to acknowledge receipt of duly Executed Assignment(s)
as provided in Exhibit B, and present for Assignee’s payment. At the Closing and upon receipt of the payment set forth in
Section 2.1 under this Agreement, Assignor will provide Escrow Agent written notice of permission, with a copy to Assignee’s
Representatives, to release immediately the Executed Assignments to Assignee. Upon the receipt of such permission from Assignor,
the Escrow Agent will then transfer the Executed Assignment(s) in Escrow to Assignee, who may then and only then record the Executed
Assignments with the applicable patent offices.

 

4.6Termination
and Survival. In the event all conditions to Closing set forth in paragraph 4.3 are not met within fifteen (15) business days
following the Effective Date, Assignee will have the right to terminate this Agreement by written notice to Assignor. Upon termination,
Assignee and the Escrow Agent will return all documents delivered to Assignee and/or the Escrow Agent under this Section 4
to Assignor, including in particular the Executed Assignment(s) and all such Executed Assignments are void ab initio. The provisions
of Sections 7 and 8 will survive any termination.

 

 

5Additional
Obligations

 

5.1Prosecution
of Applications and Maintenance of Patents. After Closing, Assignee shall have all rights to control (and the responsibility
to assume and pay for) the prosecution and maintenance of the Transferred Patents throughout the world, including the decision
whether or not to prosecute, continue prosecuting, initiate further prosecution with respect to and/or maintain any Transferred
Patent.

 

5.2Payment of
Fees. Assignor will pay any maintenance fees, annuities, and the like have a Due Date on or before May 30, 2013. Assignor hereby
gives Assignee power-of-attorney to (a) execute documents in the name of Assignor in order to effectuate the recordation of the
transfers of any portion of the Patents in an governmental filing office in the world and (b) instruct legal counsel to take steps
to pay maintenance fees and annuities that Assignor declines to pay and to make filings on behalf of Assignor prior to Closing
and otherwise preserve the assets through Closing.

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 10 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

5.3Future Cooperation.
Within forty (40) calendar days following the Effective Date, Assignor agrees to cooperate with Assignee in order to facilitate
a smooth handover of the Transferred Patents from Assignor to Assignee and, accordingly, will, at the other Party’s reasonable
request, (i) execute or cause to be executed (where appropriate), acknowledge or cause to be acknowledged (where appropriate) and
deliver or cause to be delivered (where appropriate) such further instruments and documents; and (ii) take such other action or
cause such action to be taken, including, without limitation, execution, acknowledgment, and recordation of other such papers,
and using commercially reasonable efforts to obtain the same from the respective inventors, and delivering executed documents in
a form as may be required in all relevant jurisdictions to perfect assignment, in each case (i) and (ii) as are necessary or as
either Party may reasonably request to fully perfect and effect the benefit of the transfer contemplated by this Agreement. Unless
otherwise expressly specified under this Section 5.3 or further agreed by Parties in writing, Assignor and inventors of the Transferred
Patents shall not be obligated to assist in prosecution, maintenance, litigation or licensing of the Transferred Patents or to
execute or have executed additional oaths, declarations or any other assistance after the Closing Date. Assignee agrees to compensate
Assignor for any out-of-pocket costs in relation to such assistance, if any.

 

5.4In the event
Assignee, or any successor in interest, assignee or exclusive licensee of any Transferred Patent, files any patent application
that claims, or is entitled to claim, priority from any Transferred Patent, then such patent application and any patent issuing
thereon shall be deemed to be a "Transferred Patent" and is subject to the reserved rights of Assignor or its Affiliates
as set forth in this Agreement. In no event shall this Section 5.4 be interpreted to expand the rights assigned to Assignee under
this Agreement.

 

5.5Assignee acknowledges
that the Transferred Patents may be subject to the express or implied licensing obligations of an open source license, standards
body, patent pool or other similar alliances or entities. Accordingly, Assignee acknowledges and agrees that the sale and assignment
of the Transferred Patents shall be subject to, and Assignee and its successor, exclusive licensee, shall abide by, all obligations
arising out of the foregoing obligations that relate to the Transferred Patents.

 

5.6With respect
to the licenses and other rights reserved by Assignor, the obligations of Assignee under this Agreement (other than the payment
obligation set forth in Section 2.1), and the agreements, rights, duties, and obligations between Assignor or its Affiliates and
its or their licensees, Assignee agrees to compel its successors in interest, assigns and exclusive licensees of each Transferred
Patent to abide by the terms of this Agreement.

 

6Representations
and Warranties

 

As of the Effective
Date of this Agreement, each Party represents and warrants to the other party that:

 

6.1It is a company
duly formed and validly existing under the laws of the jurisdiction of its formation and has the full corporate power and authority
to enter into, execute and deliver this Agreement and perform the obligations contained herein and it has obtained all necessary
consents, approvals, and/or other authorizations required to enter into this Agreement and to carry out its obligations hereunder;

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 11 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

6.2The execution
and delivery by such Party of this Agreement and the performance by such Party of its obligations contemplated in this Agreement
have been duly authorized by any necessary corporate or other action of such Party;

 

6.3Neither Party
has made any agreement with any third party which would entitle such third party to claim any fee, commission or reimbursement
of expenses from the other Party or any of its Affiliates as a result of such Party entering into this Agreement. That is, for
example, Assignee has not made an agreement that obligates Assignor to make any further payments to a third party as a result of
this Agreement beyond the obligations provided for in this Agreement.

 

As of the Effective
Date of this Agreement, Assignor makes the representations and warranties in Sections 6.4 through 6.8 to Assignee:

 

6.4Assignor owns
all right, title and interest to the Transferred Patents existing as of the Effective Date, including, without limitation, all
right, title and interest to sue for infringement of the Transferred Patents and has the right to make the assignments provided
in Section 3.

 

6.5To the Knowledge
of Assignor, all such Transferred Patents are free from all liens, claims, mortgages, security interests or other encumbrances,
or restrictions, except as listed on Exhibit C.

 

6.6Assignor is
responsible for the payment of all maintenance fees, annuities and other like fees for such Transferred Patents that having a due
date on or before the later of (i) the Closing Date and (ii) May 31, 2013, and Assignee shall be responsible for the payment of
all such fees due after such date above.

 

6.7To the Knowledge
of Assignor, except as listed on Exhibit C, there has been no litigation or suit filed and/or pending, or written assertion, (i)
by or against Assignor concerning the ownership, validity, registrability, enforceability or use of any Transferred Patents, or
(ii) contesting or challenging the ownership, validity, registrability or enforceability of Assignor’s right to use any Transferred
Patents. To the Knowledge of Assignor, except as listed on Exhibit C, none of the Transferred Patents has ever been found invalid,
unpatentable, or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding, and Assignor has
no Knowledge of and has not received any notice or information of any kind from any source suggesting that the Transferred Patents
may be invalid, unpatentable, or unenforceable. None of the Transferred Patents has been or is currently involved in any reexamination,
reissue, interference proceeding, or any similar proceeding except as noted in Exhibit A, and no such proceedings are pending or
threatened. If any of the Transferred Patents are terminally disclaimed to another patent or patent application, all patents and
patent applications subject to such terminal disclaimer are included in this transaction. To the extent “small entity”
fees were paid to the United States Patent and Trademark Office for any Transferred Patent, such reduced fees were then appropriate
because the payor qualified to pay “small entity” fees at the time of such payment and specifically had not licensed
rights in any of the Transferred Patents to an entity that was not a “small entity.”

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 12 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

6.8To the Knowledge
of Assignor and after conducting a review of Assignor’s legal department database of patent license agreements with regard
to the Transferred Patents, Assignor has not executed a patent license agreement with any third parties which expressly granted
a patent license under any and/or or all Transferred Patents to any third party (the date indicated in parentheses next to each
such party is expiring date), nor agreed to grant any such license in the future, except as disclosed in Exhibit C. For the avoidance
of doubt the foregoing statements in this Section do not apply to (i) any mandatory license to any governmental authority or equivalent
entity implied under any applicable law, (ii) any agreement between the Assignor or one of its Affiliates and its or their direct
or indirect suppliers, customers or partners in connection with the supply, development, sale, license, or distribution, by or
on behalf of Assignor, of products, software, technology or services, (iii) any obligation described in Section 5.5.

 

6.9Except as expressly
set forth in this Section 6, the Parties acknowledge and understand that the Transferred Patents are being sold “AS IS”
in all respects and with all faults, and without warranties or representations of any kind, express or implied, with respect to
the Transferred Patents. Assignor does not represent or warrant that the Transferred Patents are or are not of any particular scope,
valid, enforceable, or infringed by any product, service or method. Assignor further does not represent or warrant that the subject
matter disclosed in the Transferred Patents does or does not infringe the patent rights of any patent owner.

 

7Limitations
of Liability

 

7.1Notwithstanding
any provision to the contrary, Assignee shall indemnify and hold Assignor and its Affiliates harmless against all losses, costs
and expenses (including employee time and attorneys’ fees) arising from Assignee’s activities relating to defense,
enforcement or licensing of any Transferred Patents.

 

7.2EXCEPT IN THE
CASE OF ANY (1) BREACH OF CONFIDENTIALITY, OR (2) INTENTIONAL MISREPRESENTATION BY ANY PARTY:

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 13 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

		7.2.1	THE TOTAL LIABILITY OF EITHER PARTY TO THE OTHER UNDER THIS AGREEMENT WILL NOT EXCEED THE TOTAL
PAYMENT PAID BY ASSIGNEE FOR THE ASSIGNED RIGHTS; AND

 

		7.2.2	NEITHER PARTY SHALL BE LIABLE, WHETHER IN CONTRACT, IN TORT OR OTHERWISE, FOR ANY PUNITIVE, SPECIAL,
EXEMPLARY, INDIRECT OR CONSEQUENTIAL DAMAGES WHATSOEVER, OR FOR ANY LOSS OF ACTUAL OR ANTICIPATED PROFITS OR REVENUE, LOSS OF BUSINESS
OPPORTUNITY, INCREASED FINANCING OR BORROWING COSTS, INCREASED COST OF CAPITAL, LOSS OF GOODWILL, BUSINESS INTERRUPTIONS, CLAIMS
OF CUSTOMERS, INCREASED EXPENSE OF OPERATION, OR SIMILAR CLAIMS, WHICH IN ANY WAY ARISE OUT OF, RELATE TO, OR ARE A CONSEQUENCE
OF, ANY PERFORMANCE OR NONPERFORMANCE HEREUNDER OR BREACH HEREOF.

 

8Miscellaneous

 

8.1Compliance
with Laws. Notwithstanding anything contained in this Agreement to the contrary, the obligations of the Parties shall be subject
to all laws, present and future, of any Governmental Authority having jurisdiction over the Parties and this transaction, and to
orders, regulations, directions or requests of any such government.

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 14 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

8.2Confidentiality
of Terms. The Parties to this Agreement shall continue to maintain confidential all the information provided to Assignee as
had been agreed to be maintained as confidential before the Effective Date of the Agreement. All the technical and commercial information
provided to Assignee during the negotiation and performance of this Agreement, including, but not limited to, the content of this
Agreement and the existence of this Agreement, any licenses, agreements, discussions, or negotiations relating to the Transferred
Patents (including, without limitation, any licenses granted to the Transferred Patents prior to the Effective Date); and (c) any
disagreement, dispute, or litigation relating to the Transferred Patents or relating to any licenses, contracts, or agreements
concerning the Transferred Patents shall be treated as Confidential Information. The Parties shall strictly perform confidentiality
obligations specified in the Non-Disclosure Agreement entered into by the Parties on December 20, 2012 and the Common Interest
Agreement executed by the Parties together with this Agreement. Notwithstanding the foregoing provisions of this Section 8.2, nothing
in this Agreement restricts or limits Assignee’s or Assignor’s ability to disclose that Assignee is the owner of the
Transferred Patents and the fact that Assignee acquired the Transferred Patents from Assignor.

 

8.3Press Release.
The Parties shall consult with each other before issuing any press releases with respect to the subject matter of this Agreement
and shall not issue any such press releases or make any such public statements without the prior written consent of the other Party,
which shall not be unreasonably withheld.

 

8.4Governing
Law. This Agreement shall be governed by the laws of Hong Kong, without giving effect to principles of conflicts of law. All
disputes, controversies and differences between the Parties arising out of or relating to this Agreement shall be settled amicably
through negotiations in good faith. If any dispute or controversy cannot be settled amicably through negotiations within a thirty
(30) calendar day period, it shall be submitted to Hong Kong International Arbitration Centre. The award of the arbitration shall
be final and binding upon the Parties.

 

8.5Entire Agreement
and Miscellaneous Terms. The terms and conditions of this Agreement, including its exhibits, constitute the entire agreement
between the Parties with respect to the subject matter hereof, and, except where explicitly stated otherwise, merges and supersedes
all prior and contemporaneous agreements, understandings, negotiations and discussions. Neither of the Parties shall be bound by
any conditions, definitions, warranties, understandings or representations with respect to the subject matter of this Agreement
other than as expressly provided herein. The section headings contained in this Agreement are for reference purposes only and shall
not affect in any way the meaning or interpretation of this Agreement. No oral explanation or oral information by either Party
shall alter the meaning or interpretation of this Agreement. No amendments or modifications will be effective unless in writing
signed by an authorized representative of each Party. These terms and conditions will prevail notwithstanding any different, conflicting
or additional terms and conditions which may appear in any writing not expressly incorporated into this Agreement. This Agreement
may be executed in four (4) or more counterparts, all of which, taken together, shall be regarded as one and the same instrument.
The following exhibits are attached hereto and incorporated fully herein: Exhibit A (entitled “Transferred Patents”);
Exhibit B (entitled “Assignment of Patent Rights”); Exhibit C (entitled “Existing Encumbrances”);
Exhibit D (entitled “Initial Deliverables”); Exhibit E (entitled “Common Interest Agreement”);
Exhibit F (entitled “Escrow Agreement”).

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 15 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

8.6Notices.
All notices required or permitted to be given hereunder must be in writing, make reference to this Agreement, be delivered by hand,
be dispatched by prepaid air courier or by registered or certified airmail, postage prepaid, addressed as follows:

 

	
        If to Assignor:

         
	If to Assignee:	 
	
        Director of Licensing

        Intellectual Property Rights Department

        Huawei Technologies Co., Ltd.

        Section B, Huawei Industrial Base

        Bantian, Longgang District

        Shenzhen 518129, P.R.China
	
         

        Joseph Beyers

        Inventergy, Inc.

        19925 Stevens Creek Boulevard, Suite 100

        Cupertino, CA 95014

         

         

Such notices shall be deemed served when
received by addressee or, if delivery is not accomplished by reason of some fault of the addressee, when tendered for delivery.
Either Party may give written notice of a change of address and, after notice of the change has been received, any notice or request
must thereafter be given to that Party at that changed address.

 

8.7Relationship
of Parties. The Parties are independent of each other. Neither Party has any express or implied right or authority to assume
or create any obligations on behalf of the other or to bind the other to any contract, agreement or undertaking with any third
party. Nothing in this Agreement shall be construed to create an employment or agency relationship between Assignor and Assignee.
In addition, this Agreement is solely for the benefit of the Parties, and nothing herein (express, implied or otherwise) is intended
or shall be construed to confer upon or give to any person, other than the Parties and their permitted successors or assigns, any
rights or remedies under or by reason of this Agreement.

 

8.8Severability.
The terms and conditions stated herein are declared to be severable. If any paragraph, provision or clause in this Agreement is
found or held to be invalid or unenforceable in any jurisdiction in which this Agreement is being performed, the remainder of this
Agreement will remain valid and enforceable to the extent the purpose of this Agreement can be effected, and the Parties shall
use good faith to negotiate a substitute, valid and enforceable provision which most nearly effects the Parties’ intent in
entering into this Agreement.

 

8.9Waiver.
Failure by either Party to enforce any term of this Agreement shall not be deemed a waiver of future enforcement of that or any
other term in this Agreement or any other agreement that may be in place between the Parties.

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 16 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

8.10 Successors
and Assigns. This Agreement shall inure to the benefit of and be binding on Assignee and Assignor and their respective successors
and assigns.

 

[Remainder of this page intentionally
left blank]

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 17 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

In witness whereof,
the Parties have executed this Patent Rights Assignment Agreement as of the Effective Date of May 15, 2013:

 

 

 

	Huawei Technologies Co., Ltd. (“Assignor”)	 	Inventergy, Inc. (“Assignee”)	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	Signature	 	Signature	 
	 	 	 	 
	Jianxin Ding (Jason)	 	Joseph W. Beyers	 
	Printed Name	 	Printed Name	 
	 	 	 	 
	Director of Intellectual Property	 	Chairman & CEO	 
	Title	 	Title	 
	 	 	 	 
	May 15, 2013	 	May 15, 2013	 
	Date	 	Date	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 18 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

EXHIBIT A

 

Transferred Patents

(EP Countries Include All Validated Countries
for each Issued European Patent)

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	1	BR	BRPI614848A	2006-07-26	BRPI0614848A2	2011-04-19	 
	1	CN	CN200510119756A	2005-11-04	CN100502402C	2009-06-17	 
	1	CN	CN200680011706A	2006-07-26	CN101189850B	2012-02-22	 
	1	EP	EP2006254341A	2006-08-18	EP1755310B1	2011-06-08	DE、ES、FR、GB、

IT
	1	IN	IN2008CN454A	2008-01-28	IN254557B	2012-11-23	 
	1	US	US2006506581A

 11/506,581	18 Aug 2006	US7835352B2	2010-11-16	 
	2	CN	CN200510093678A	2005-09-01	CN1925671 

CN100551148C   	2007-03-07	 
	2	CN	CN200680011893A	2006-09-01	CN101156498 

CN101156498B  	2011-10-26	 
	2	EP	EP2006775581A	2006-09-01	EP1871134B1	2009-12-16	DE、FR、GB
	2	WO	WO2006CN2264A	2006-09-01	WO2007025487A1	2007-03-08	 
	3	CN	CN200610058041A	2006-02-28	CN101031004B	2010-05-12	 
	3	CN	CN200680012256A	2006-10-31	CN101160940B	2010-08-11	 
	3	EP	EP2006805125A	2006-10-31	EP1993274A1	2008-11-19	 
	3	US	 US2007668532A 

11/668,523	2007-01-30	US8149824B2	2012-04-03	 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 19 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	3	WO	WO2006CN2924A	2006-10-31	WO2007098654A1	2007-09-07	 
	4	CN	CN200680011910A	2006-10-24	CN101156398B	2010-10-27	 
	4	CN	CN200510101368A	2005-11-11	CN1964365B	2011-06-22	 
	4	EP	EP200623462A	2006-11-10	EP1786216B1	2009-12-30	DE、FR
	4	US	US2006595768A

11/595,768	2006-11-10	US7693141B2	2010-04-06	 
	4	WO	WO2006CN2841A	2006-10-24	WO2007054011A1	2007-05-18	 
	5	CN	CN2005100280747	2005-07-22	 	 	 
	5	CN	CN200610106654A	2006-07-21	CN1901550B	2011-08-10	 
	5	EP	EP2006761541A	2006-07-21	EP1909434A1	2008-04-09	 
	5	EP	EP2009160916A	2006-07-21	EP2086203A3	2009-10-28	 
	5	US	US200817423A

[08/0113,669] 12/017,423	2008-01-22	US7948955B2	2011-05-24	 
	5	WO	WO2006CN1806A	2006-07-21	WO2007009396A1	2007-01-25	 
	6	CN	CN200410078266.4	2005-09-21	 	 	 
	6	CN	CN200510103571A	2005-09-21	CN 1764140A	2007-03-07	 
	6	EP	EP2005791501A	2005-09-21	EP1796326B1	2012-01-18	FR、DE、IT、NL、

SE、GB
	6	WO	WO2005CN1523A	2005-09-21	WO2006032204A1	2006-03-30	 
	7	CN	CN200510108129A	2005-09-29	CN1941739B	2010-06-23	 
	7	CN	CN200510098402A	2005-09-06	CN1929627B	2012-02-01	 
	7	CN	CN200510108128A	2005-09-29	CN1941774B	2012-07-04	 
	7	EP	EP200618705A	2006-09-06	EP1761077B1	2008-08-27	DE、FR、SE

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 20 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	7	US	US2006516946A  

11/516,946	2006-09-06	US7787878B2	2010-08-31	 
	7	WO	WO2006CN2299A	2006-09-06	WO2007028332A1	2007-03-15	 
	8	CN	CN   200710167705.2	2004-10-05	 	 	 
	8	CN	CN200410079321A	2004-10-05	CN1758649B	2010-04-28	 
	8	EP	EP2005795754A	2005-10-08	EP1798918A1	2007-06-20	 
	8	US	US2007703709A  11/703,709	2007-02-08	US7792116B2	2010-09-07	 
	8	WO	WO2005CN1640A	2005-10-08	WO2006037276A1	2006-04-13	 
	9	CN	CN200610077923A	2006-04-26	CN100563235C	2009-11-25	 
	9	CN	CN200780000211A	2007-01-09	CN101313543B	2011-07-20	 
	9	EP	EP2007702010A	2007-01-09	EP1973283B1	2010-09-29	FR、DE、GB
	9	US	US2008170227A  

'12/170,227	2008-07-09	US8213419B2	2012-07-03	 
	9	WO	WO2007CN78A	2007-01-09	WO2007079679A1	2007-07-19	 
	10	CN	CN200510026737A	 2005.06.14	CN1881961  

CN100438515C	2006-12-20	 
	10	CN	CN200510026714A	2005-06-13	CN1881959  

CN100411398C	2006-12-20	 
	10	CN	CN200510026736A	2005-06-14	CN1881960  

CN100426805C	2006-12-20	 
	10	CN	CN200680012195A	2006-05-25	CN101160799B	2011-04-20	 
	10	EP	EP20060741982	2006.05.25	EP1796312A4  EP1796312A1	2007-06-13	 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 21 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	10	US	US2007680234A  

11/680,234	2007-02-28	US7881317B2	2011-02-01	 
	10	WO	WO2006CN1094A	2006-05-25	WO2006133622A1	2006-12-21	 
	11	CN	CN200510034992A	2005-05-29	CN100563282C  

'CN 1870691	2009-11-25	 
	11	EP	EP2006741937A	2006-05-22	EP1786162B1	2009-09-30	DE、GB
	11	US	US2007707759A  11/707,759	2007-02-16	US8335221B2	2012-12-18	 
	11	WO	WO2006CN1049A	2006-05-22	WO2006128356A1	2006-12-07	 
	12	BR	BRPI0613589A2	2006-08-10	BRPI0613589A2	2011-01-18	 
	12	CN	CN200510093052A	2005-08-25	CN1921459A  'CN 1921459	2007-02-28	 
	12	CN	CN200680012205A	2006-08-10	CN101161011B	2011-08-10	 
	12	EP	EP2006775336A	2006-08-10	EP1816887B1	2010-05-05	FR、DE
	12	IN	IN2007KN4950A	2007-12-20	IN200704950P2	2008-08-01	 
	12	JP	JP2008527289A	2006-08-10	JP04619441B2	2011-01-26	 
	12	RU	RU2008101969A	2006-08-10	RU2408154C2	2010-12-27	 
	12	US	US2007821113A  

11/821,113	2007-06-21	US8125995B2	2012-02-28	 
	12	WO	WO2006CN2018A	2006-08-10	WO2007022692A1	2007-03-01	 
	13	CN	CN200510032840A	2005-01-14	CN100459569C  CN 1805408A	2009-02-04	 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 22 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	13	EP	EP2006705441A	2006-01-09	EP1718014B1	2008-10-15	FR、SE
	13	US	US2003591218A  

10/591,218	2007-11-21	US7898943B2	2011-03-01	 
	13	WO	WO2006CN18A	2006-01-09	WO2006074596A1	2006-07-20	 
	14	CN	CN200680013147A	2006-06-14	CN101164290A	2008-04-16	 
	14	CN	CN200510098546A	2005-09-02	CN100479417C  

'CN 1925450	2009-04-15	 
	14	EP	EP2006119909A	2006-08-31	EP1760986A1	2007-03-07	 
	14	US	US2006469796A  

11/469,796	2006-09-01	US8108526B2	2012-01-31	 
	14	WO	WO2006CN1325A	2006-06-14	WO2007025429A1	2007-03-08	 
	15	CN	CN200610170447A	2006-12-30	CN101212309B	2011-06-15	 
	15	EP	EP2007846226A	2007-12-29	EP2037627B1	2012-03-14	DE、FR、IT
	15	US	US2009354289A  

12/354289	2009-01-15	US8116322B2	2012-02-14	 
	15	WO	WO2007CN71400A	2007-12-29	WO2008083606A1	2008-07-17	 
	16	CN	CN200810189659.0	2006-06-26	 	 	 
	16	CN	CN200610093956A	2006-06-26	CN1996968B	2010-04-14	 
	16	EP	EP2007721793A	2007-06-25	EP2034670B1	2012-06-13	FR、DE、IT
	16	US	US2008342546A  

12/342,546	2008-12-23	US7899065B2	2011-03-01	 
	16	WO	WO2007CN70177A	2007-06-25	WO2008003252A1	2008-01-10	 
	17	CN	CN200680012331A	2006-08-22	CN101161019A	2008-04-09	 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 23 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	17	CN	CN200510110891A	2005-11-29	CN100442930C  

'CN 1893724	 	 
	17	EP	EP2006775455A	2006-08-22	EP1898658B1	2009-12-02	DE
	17	WO	WO2006CN2137A	2006-08-22	WO2007062560A1	2007-06-07	 
	18	CN	CN200610165838.1	2006-12-13	 	 	 
	18	CN	CN200710107595.0	2007-05-21	 	 	 
	18	CN	CN200610062951A	2006-09-29	CN100471140C 

'CN 1933431	2009-03-18	 
	18	EP	EP2007817016A	2007-09-29	EP1983688B1	2012-04-25	FR、DE、GB
	18	EP	EP07871768.3	2007-12-12	 	 	 
	18	WO	PCT/CN2007/071220	2007-12-12	WO 2008/086720	 	 
	18	WO	PCT/CN2008/071008	2008-05-19	WO 2008/141580	 	 
	18	US	US2008211555A  

12/211555	2008-09-16	US20090016233A1	2009-01-15	 
	18	WO	WO2007CN70825A	2007-09-29	WO2008043304A1	2008-04-17	 
	19	CN	CN200510085400A	2005-07-27	CN1905472B	2010-05-05	 
	19	EP	EP2006761564A	2006-07-25	EP1914937B2	2013-01-23	GB、FR、DE
	19	WO	WO2006CN1834A	2006-07-25	WO2007012270A1	2007-02-01	 
	20	CN	CN200510034409A	2005-04-22	CN100546308C	2009-09-30	 
	20	US	US2007856152A  

11/856,152	2007-09-17	US7653076B2	2010-01-26	 
	20	WO	WO2006CN780A	2006-04-24	WO2006111104A1	2006-10-26	 
	21	CN	CN200410062977A	2004-06-30	CN100493069C  

CN 1716945A	2006-01-04	 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 24 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	21	CN	CN200410062978A 

(CN100349411C)	2004-06-30	CN100349411C  

CN 1716870 	2007-11-14	 
	21	EP	EP2005759437A	2005-06-30	EP1739900B1	2008-10-29	ES、FR、PT、SE
	21	US	US2006558619A	2006-11-10	US7583612B2	2009-09-01	 
	21	WO	WO2005CN958A	2005-06-30	WO2006002597A1	2006-01-12	 
	22	CN	CN200510051044A  

200510051044.8	25 Feb 2005	CN100499656C  

CN 1825848A	2009-06-10	 
	22	US	US20080049705A1   

US2007844481A	27 Feb 2006	US8085712B2	2011-12-27	 
	22	WO	WO2006CN281A	2006-02-27	WO2006089491A1	2006-08-31	 
	23	CN	CN200610065066A  

200610065066.4	2006-03-16	CN100583918C  

CN 1870686A	2010-01-20	 
	23	CN	CN200680012823A	2006-11-22	CN101160869A  

CN 101160869A	 	 
	23	US	US2006618597A	2006-12-29	US7710880B2	2010-05-04	 
	23	WO	WO2006CN3144A	2006-11-22	WO2007104199A1	2007-09-20	 
	24	CN	CN200910118794A  

200910118794.0 	2009-03-16	CN101841888B	2012-06-27	 
	24	EP	EP2010753112A  

EP10753112.1	2010-03-16	EP2439979A1	2012-04-11	 
	24	US	US13235062A	2011-09-16	US8224325B2	2012-07-17	 
	24	WO	WO2010CN71057A	2010-03-16	WO2010105545A1	2010-09-23	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 25 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	25	AU	AU2003271027A	2003-09-22	AU2003271027B2	2007-08-09	 
	25	CN	CN2002144191A	2002-10-18	CN1275419C	2006-09-13	 
	25	US	US2003531569A	2005-04-18	US8195942B2	2012-06-05	 
	25	WO	WO2003CN801A	2003-09-22	WO2004036828A1	2004-04-29	 
	26	CN	CN200510000097A 

200510000097.7	07 Jan 2005	CN100574185C  

CN 1801698A	2009-12-23	 
	26	EP	EP2005848163A	2005-12-31	EP1835652B1	2010-06-16	DE、GB
	26	US	US2007774271A   

11774271	2007-07-06	US20070294186A1	2007-12-20	 
	26	WO	WO2005CN2429A	2005-12-31	WO2006072212A1	2006-07-13	 
	27	Argentina	ARP20060102194A	26 May 2006	AR053615	2007-05-07	 
	27.1	CN	CN200510071538A	2005-05-27	CN100461942C  

CN 1870812A	2009-02-11	 
	27.1	DE	DE602006007648T	2006-04-03	DE602006007648D1  

DE 60 2006 031 

091.9	2009-08-20	 
	27.1	EP	EP2006722247A	2006-04-03	EP1755311B1	2009-07-08	GB、FR、DE
	27.1	TW	TW2006118609A	2006-05-25	TWI314414B	2009-09-01	 
	27.1	US	US2006629346A   

11/629,346 	2007-05-07	US20080209532A1	2008-08-28	 
	27.1	WO	WO2006CN595A	2006-04-03	WO2006125359A1	2006-11-30	 
	27.2	CN	CN200510070351A    

200510070351.0	2005-04-30	CN100571134C  

CN 1859093A	2009-12-16	 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 26 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	27.2	EP	EP2006741743A	2006-04-27	EP1879324B1	2012-08-01	DE、ES、FR、GB、

IT
	27.2	US	US2007896389A	2007-08-31	US8335487B2	2012-12-18	 
	27.2	WO	WO2006CN822A	2006-04-27	WO2006116921A1	2006-11-09	 
	28	CN	CN200610111254.6	2006-08-17	 	 	 
	28	CN	CN200610141030A	2006-09-28	CN101128049B	2012-07-04	 
	28	EP	EP2007785297A	2007-08-09	EP2056536B1	2012-01-25	FR、DE、GB
	28	WO	WO2007CN2390A	2007-08-09	WO2008022536A1	2008-02-28	 
	29	Argentina	ARP20050103360A	2005-08-11	AR50123A1	2006-09-27	 
	29	BR	BRPI507677A	2005-08-11	BR200507677A	2007-07-17	 
	29	CN	CN200410059164A	2004-08-11	CN1735268A	2006-02-15	 
	29	CN	CN200410059165A	2004-08-11	CN100349473C  

CN 1735232A	
    2007-11-14
 2006-02-15	 
	29	EP	EP2005774458A	2005-08-11	EP1713241A1	2006-10-18	 
	29	IN	IN2006CN4422A	2006-12-01	IN246930B	2011-03-25	 
	29	Indonesia	IDW-00200602090	2005-08-11	ID0024111 	 	 
	29	RU	RU2006130835A	2005-08-11	RU2370904C2	2009-10-20	 
	29	US	US2006489208A	2006-07-19	US7787608B2	2010-08-31	 
	29	WO	WO2005CN1241A	2005-08-11	WO2006015551A1	2006-02-16	 
	30	CN	CN200710079246A	2007-02-13	CN101247632A	2008-08-20	 
	30	CN	CN200780000599A	2007-11-19	CN101517960A	2009-08-26	 
	30	EP	EP2008101535A	2008-02-12	EP1959632A1	2008-08-20	 
	30	IN	IN5391/DELNP/2009	19 Nov 2007	IN5391/DELNP/2009	 	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 27 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	30	RU	RU2009134133A	2007-11-19	RU2434351C2	2011-11-20	 
	30	US	US2009539890A	2009-08-12	US8185105B2	2012-05-22	 
	30	US	US13414770A	2012-03-08	US8417240B2	2013-04-09	 
	30	WO	WO2007CN71090A	2007-11-19	WO2008098459A1	2008-08-21	 
	31	CN	CN   200610079107.5	2006-04-29	 	 	 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 28 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	31	CN	CN200610099533A	2006-07-28	CN101064661B	2011-08-24	 
	31	CN	CN200780000297A	2007-02-08	CN101317438B	2012-04-25	 
	31	EP	EP2007702308A	2007-02-08	EP1881689B1	2010-06-02	FR、DE、GB
	31	US	US2007881806A	2007-07-27	US20080032686A1	2008-02-07	 
	31	WO	WO2007CN435A	2007-02-08	WO2007124641A1	2007-11-08	 
	32	CN	CN200610035050A	2006-04-18	CN101056452B	2010-05-12	 
	32	CN	CN200680013004A	2006-11-29	CN101167374B	2011-02-09	 
	32	EP	EP20077802A	2007-04-17	EP 1848190A1	2007-10-24	 
	32	US	US2007787527A	2007-04-17	US7764953B2	2010-07-27	 
	32	WO	WO2006CN3214A	2006-11-29	WO2007118380A1	2007-10-25	 
	33	CN	CN200680011755A	2006-11-01	CN101156426B	2011-02-16	 
	33	CN	CN200610057699A	2006-02-24	CN101026653B	2011-08-24	 
	33	EP	EP2007101173A	2007-01-25	EP1826985B1	2009-10-28	FR、DE、GB
	33	US	US2007698891A	2007-01-29	US20070201635A1	2007-08-30	 
	33	WO	WO2006CN2933A	2006-11-01	WO2007095802A1	2007-08-30	 
	34	CN	CN200510114277A	2005-10-21	CN100487788C	2009-05-13	 
	34	EP	EP2006805015A	2006-10-20	EP1950737B1	2010-05-26	DE、GB
	34	US	US2008106693A	2008-04-21	US20080205279A1	2008-08-28	 
	34	WO	WO2006CN2806A	2006-10-20	WO2007045187A1	2007-04-26	 
	35	CN	CN200610140147A	2006-09-30	CN101155148B	2012-02-22	 
	35	EP	EP2007816481A	2007-09-29	EP2068513B1	2010-11-24	DE、IT
	35	US	US2009413015A  

12/413,015  	2009-03-27	US7920579B2	2011-04-05	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 29 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	35	WO	WO2007CN2867A	2007-09-29	WO2008040191A1	2008-04-10	 
	36	CN	CN200710095931A	2007-03-30	CN101277343B	2012-01-04	 
	36	EP	EP2008706632A	2008-02-03	EP2120440B1	2011-10-19	FR、DE、GB
	36	WO	WO2008CN70257A	2008-02-03	WO2008119272A1	2008-10-09	 
	37	CN	CN200610079110A	2006-04-29	CN101064680B	2010-04-21	 
	37	EP	EP2007720936A	2007-04-24	EP2015592B1	2012-07-11	DE、GB
	37	WO	WO2007CN1363A	2007-04-24	WO2007124684A1	2007-11-08	 
	38	CN	CN200510034345A	2005-04-21	CN 1855961 CN100531267C	2009-08-19	 
	38	EP	EP2006741698A	2006-04-21	EP1874016A1	2008-01-02	 
	38	US	US2007875195A	2007-10-19	US7986775B2	2011-07-26	 
	38	WO	WO2006CN754A	2006-04-21	WO2006111100A1	2006-10-26	 
	39	CN	CN2001123948A	2001-08-07	CN1400843A	2003-03-05	 
	39	CN	CN2001123948A	2001-08-07	CN1177508C	2004-11-24	 
	39	EP	EP2002719621A	2002-03-29	EP1420605B1	2007-11-28	 
	39	RU	RU2004104321A	2002-03-29	RU2267865C2	2006/1/10	 
	39	US	US2003486322A   

10486322	29 Mar 2002	US7349693B2	2008/3/25	 
	39	WO	WO2002CN219A	2002-03-29	WO2003015437A1	2003-02-20	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 30 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

PAGE INTENTIONALLY LEFT BLANK

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 31 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

EXHIBIT B

ASSIGNMENT OF PATENT RIGHTS

 

For good and valuable consideration, the
receipt of which is hereby acknowledged, Huawei Technologies Co., Ltd., a [Chinese] Corporation, having offices at Administration
Building Huawei Technologies Co., Ltd. Bantian Longgang District, Shenzhen 518129, P. R. China (“Assignor”) does hereby
sell, assign, transfer, and convey unto Inventergy, Inc., a Delaware corporation, having offices at 19925 Stevens Creek Boulevard,
Suite 100, Cupertino, California, United States of America (“Assignee”) or its designees, all right, title, and interest
that exist as of May 15, 2013 and may exist in the future in and to any and all of the following (collectively, the “Patent
Rights”), with an Effective Date of May 15, 2013:

 

(a)the
provisional patent applications, patent applications and patents listed in the table below (the “Patents”)
(EP Countries Include All Validated Countries for each
Issued European Patent); 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	1	BR	BRPI614848A	2006-07-26	BRPI0614848A2	2011-04-19	 
	1	CN	CN200510119756A	2005-11-04	CN100502402C	2009-06-17	 
	1	CN	CN200680011706A	2006-07-26	CN101189850B	2012-02-22	 
	1	EP	EP2006254341A	2006-08-18	EP1755310B1	2011-06-08	DE、ES、FR、

GB、IT
	1	IN	IN2008CN454A	2008-01-28	IN254557B	2012-11-23	 
	1	US	US2006506581A 

11/506,581	18 Aug 2006	US7835352B2	2010-11-16	 
	2	CN	CN200510093678A	2005-09-01	CN1925671  

CN100551148C   	2007-03-07	 
	2	CN	CN200680011893A	2006-09-01	CN101156498   

CN101156498B  	2011-10-26	 
	2	EP	EP2006775581A	2006-09-01	EP1871134B1	2009-12-16	DE、FR、GB
	2	WO	WO2006CN2264A	2006-09-01	WO2007025487A1	2007-03-08	 
	3	CN	CN200610058041A	2006-02-28	CN101031004B	2010-05-12	 
	3	CN	CN200680012256A	2006-10-31	CN101160940B	2010-08-11	 
	3	EP	EP2006805125A	2006-10-31	EP1993274A1	2008-11-19	 
	3	US	 US2007668532A   

11/668,523	2007-01-30	US8149824B2	2012-04-03	 
	3	WO	WO2006CN2924A	2006-10-31	WO2007098654A1	2007-09-07	 
	4	CN	CN200680011910A	2006-10-24	CN101156398B	2010-10-27	 
	4	CN	CN200510101368A	2005-11-11	CN1964365B	2011-06-22	 
	4	EP	EP200623462A	2006-11-10	EP1786216B1	2009-12-30	DE、FR
	4	US	US2006595768A  

11/595,768	2006-11-10	US7693141B2	2010-04-06	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 32 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family 

No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP 

Countries 
	4	WO	WO2006CN2841A	2006-10-24	WO2007054011A1	2007-05-18	 
	5	CN	CN2005100280747	2005-07-22	 	 	 
	5	CN	CN200610106654A	2006-07-21	CN1901550B	2011-08-10	 
	5	EP	EP2006761541A	2006-07-21	EP1909434A1	2008-04-09	 
	5	EP	EP2009160916A	2006-07-21	EP2086203A3	2009-10-28	 
	5	US	US200817423A  

[08/0113,669] 

12/017,423	2008-01-22	US7948955B2	2011-05-24	 
	5	WO	WO2006CN1806A	2006-07-21	WO2007009396A1	2007-01-25	 
	6	CN	CN200410078266.4	2005-09-21	 	 	 
	6	CN	CN200510103571A	2005-09-21	CN 1764140A	2007-03-07	 
	6	EP	EP2005791501A	2005-09-21	EP1796326B1	2012-01-18	FR、DE、IT、

NL、SE、GB
	6	WO	WO2005CN1523A	2005-09-21	WO2006032204A1	2006-03-30	 
	7	CN	CN200510108129A	2005-09-29	CN1941739B	2010-06-23	 
	7	CN	CN200510098402A	2005-09-06	CN1929627B	2012-02-01	 
	7	CN	CN200510108128A	2005-09-29	CN1941774B	2012-07-04	 
	7	EP	EP200618705A	2006-09-06	EP1761077B1	2008-08-27	DE、FR、SE
	7	US	US2006516946A  

11/516,946	2006-09-06	US7787878B2	2010-08-31	 
	7	WO	WO2006CN2299A	2006-09-06	WO2007028332A1	2007-03-15	 
	8	CN	CN   200710167705.2	2004-10-05	 	 	 
	8	CN	CN200410079321A	2004-10-05	CN1758649B	2010-04-28	 
	8	EP	EP2005795754A	2005-10-08	EP1798918A1	2007-06-20	 
	8	US	US2007703709A  

11/703,709	2007-02-08	US7792116B2	2010-09-07	 
	8	WO	WO2005CN1640A	2005-10-08	WO2006037276A1	2006-04-13	 
	9	CN	CN200610077923A	2006-04-26	CN100563235C	2009-11-25	 
	9	CN	CN200780000211A	2007-01-09	CN101313543B	2011-07-20	 
	9	EP	EP2007702010A	2007-01-09	EP1973283B1	2010-09-29	FR、DE、GB
	9	US	US2008170227A  

'12/170,227	2008-07-09	US8213419B2	2012-07-03	 
	9	WO	WO2007CN78A	2007-01-09	WO2007079679A1	2007-07-19	 
	10	CN	CN200510026737A	 2005.06.14	CN1881961  

CN100438515C	2006-12-20	 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 33 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family

 No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP 

Countries 
	10	CN	CN200510026714A	2005-06-13	CN1881959  

CN100411398C	2006-12-20	 
	10	CN	CN200510026736A	2005-06-14	CN1881960  

CN100426805C	2006-12-20	 
	10	CN	CN200680012195A	2006-05-25	CN101160799B	2011-04-20	 
	10	EP	EP20060741982	2006.05.25	EP1796312A4  

EP1796312A1	2007-06-13	 
	10	US	US2007680234A  

11/680,234	2007-02-28	US7881317B2	2011-02-01	 
	10	WO	WO2006CN1094A	2006-05-25	WO2006133622A1	2006-12-21	 
	11	CN	CN200510034992A	2005-05-29	CN100563282C  

'CN 1870691	2009-11-25	 
	11	EP	EP2006741937A	2006-05-22	EP1786162B1	2009-09-30	DE、GB
	11	US	US2007707759A  

11/707,759	2007-02-16	US8335221B2	2012-12-18	 
	11	WO	WO2006CN1049A	2006-05-22	WO2006128356A1	2006-12-07	 
	12	BR	BRPI0613589A2	2006-08-10	BRPI0613589A2	2011-01-18	 
	12	CN	CN200510093052A	2005-08-25	CN1921459A 'CN 

1921459	2007-02-28	 
	12	CN	CN200680012205A	2006-08-10	CN101161011B	2011-08-10	 
	12	EP	EP2006775336A	2006-08-10	EP1816887B1	2010-05-05	FR、DE
	12	IN	IN2007KN4950A	2007-12-20	IN200704950P2	2008-08-01	 
	12	JP	JP2008527289A	2006-08-10	JP04619441B2	2011-01-26	 
	12	RU	RU2008101969A	2006-08-10	RU2408154C2	2010-12-27	 
	12	US	US2007821113A  

11/821,113	2007-06-21	US8125995B2	2012-02-28	 
	12	WO	WO2006CN2018A	2006-08-10	WO2007022692A1	2007-03-01	 
	13	CN	CN200510032840A	2005-01-14	CN100459569C  

CN 1805408A	2009-02-04	 
	13	EP	EP2006705441A	2006-01-09	EP1718014B1	2008-10-15	FR、SE
	13	US	US2003591218A  

10/591,218	2007-11-21	US7898943B2	2011-03-01	 
	13	WO	WO2006CN18A	2006-01-09	WO2006074596A1	2006-07-20	 
	14	CN	CN200680013147A	2006-06-14	CN101164290A	2008-04-16	 
	14	CN	CN200510098546A	2005-09-02	CN100479417C  

'CN 1925450	2009-04-15	 
	14	EP	EP2006119909A	2006-08-31	EP1760986A1	2007-03-07	 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 34 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP Countries 
	14	US	US2006469796A  

11/469,796	2006-09-01	US8108526B2	2012-01-31	 
	14	WO	WO2006CN1325A	2006-06-14	WO2007025429A1	2007-03-08	 
	15	CN	CN200610170447A	2006-12-30	CN101212309B	2011-06-15	 
	15	EP	EP2007846226A	2007-12-29	EP2037627B1	2012-03-14	DE、FR、IT
	15	US	US2009354289A  

12/354289	2009-01-15	US8116322B2	2012-02-14	 
	15	WO	WO2007CN71400A	2007-12-29	WO2008083606A1	2008-07-17	 
	16	CN	CN200810189659.0	2006-06-26	 	 	 
	16	CN	CN200610093956A	2006-06-26	CN1996968B	2010-04-14	 
	16	EP	EP2007721793A	2007-06-25	EP2034670B1	2012-06-13	FR、DE、IT
	16	US	US2008342546A  

12/342,546	 2008-12-23	US7899065B2	2011-03-01	 
	16	WO	WO2007CN70177A	2007-06-25	WO2008003252A1	2008-01-10	 
	17	CN	CN200680012331A	2006-08-22	CN101161019A	2008-04-09	 
	17	CN	CN200510110891A	2005-11-29	CN100442930C  

'CN 1893724	 	 
	17	EP	EP2006775455A	2006-08-22	EP1898658B1	2009-12-02	DE
	17	WO	WO2006CN2137A	2006-08-22	WO2007062560A1	2007-06-07	 
	18	CN	CN200610165838.1	2006-12-13	 	 	 
	18	CN	CN200710107595.0	2007-05-21	 	 	 
	18	CN	CN200610062951A	2006-09-29	CN100471140C  

'CN 1933431	2009-03-18	 
	18	EP	EP2007817016A	2007-09-29	EP1983688B1	2012-04-25	FR、DE、GB
	18	EP	EP07871768.3	2007-12-12	 	 	 
	18	WO	PCT/CN2007/071220	2007-12-12	WO 2008/086720	 	 
	18	WO	PCT/CN2008/071008	2008-05-19	WO 2008/141580	 	 
	18	US	US2008211555A  

12/211555	2008-09-16	US20090016233A1	2009-01-15	 
	18	WO	WO2007CN70825A	2007-09-29	WO2008043304A1	2008-04-17	 
	19	CN	CN200510085400A	2005-07-27	CN1905472B	2010-05-05	 
	19	EP	EP2006761564A	2006-07-25	EP1914937B2	2013-01-23	GB、FR、DE
	19	WO	WO2006CN1834A	2006-07-25	WO2007012270A1	2007-02-01	 
	20	CN	CN200510034409A	2005-04-22	CN100546308C	2009-09-30	 
	20	US	US2007856152A  

11/856,152	2007-09-17	US7653076B2	2010-01-26	 
	20	WO	WO2006CN780A	2006-04-24	WO2006111104A1	2006-10-26	 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 35 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family

 No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP

 Countries 
	21	CN	CN200410062977A	2004-06-30	CN100493069C  

CN 1716945A	2006-01-04	 
	21	CN	CN200410062978A 

(CN100349411C)	2004-06-30	CN100349411C  

CN 1716870 	2007-11-14	 
	21	EP	EP2005759437A	2005-06-30	EP1739900B1	2008-10-29	ES、FR、PT、

SE
	21	US	US2006558619A	2006-11-10	US7583612B2	2009-09-01	 
	21	WO	WO2005CN958A	2005-06-30	WO2006002597A1	2006-01-12	 
	22	CN	CN200510051044A  

200510051044.8	25 Feb 2005	CN100499656C  

CN 1825848A	2009-06-10	 
	22	US	US20080049705A1   

US2007844481A	27 Feb 2006	US8085712B2	2011-12-27	 
	22	WO	WO2006CN281A	2006-02-27	WO2006089491A1	2006-08-31	 
	23	CN	CN200610065066A  

200610065066.4	2006-03-16	CN100583918C  

CN 1870686A	2010-01-20	 
	23	CN	CN200680012823A	2006-11-22	CN101160869A  

CN 101160869A	 	 
	23	US	US2006618597A	2006-12-29	US7710880B2	2010-05-04	 
	23	WO	WO2006CN3144A	2006-11-22	WO2007104199A1	2007-09-20	 
	24	CN	CN200910118794A  

200910118794.0 	2009-03-16	CN101841888B	2012-06-27	 
	24	EP	EP2010753112A  

EP10753112.1	2010-03-16	EP2439979A1	2012-04-11	 
	24	US	US13235062A	2011-09-16	US8224325B2	2012-07-17	 
	24	WO	WO2010CN71057A	2010-03-16	WO2010105545A1	2010-09-23	 
	25	AU	AU2003271027A	2003-09-22	AU2003271027B2	2007-08-09	 
	25	CN	CN2002144191A	2002-10-18	CN1275419C	2006-09-13	 
	25	US	US2003531569A	2005-04-18	US8195942B2	2012-06-05	 
	25	WO	WO2003CN801A	2003-09-22	WO2004036828A1	2004-04-29	 
	26	CN	CN200510000097A  

200510000097.7	07 Jan 2005	CN100574185C  

CN 1801698A	2009-12-23	 
	26	EP	EP2005848163A	2005-12-31	EP1835652B1	2010-06-16	DE、GB
	26	US	US2007774271A   

11774271	2007-07-06	US20070294186A1	2007-12-20	 
	26	WO	WO2005CN2429A	2005-12-31	WO2006072212A1	2006-07-13	 
	27	Argentina	ARP20060102194A	26 May 2006	AR053615	2007-05-07	 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 36 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family 

No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP 

Countries 
	27.1	CN	CN200510071538A	2005-05-27	CN100461942C  

CN 1870812A	2009-02-11	 
	27.1	DE	DE602006007648T	2006-04-03	DE602006007648D1  

DE 60 2006 031 

091.9	2009-08-20	 
	27.1	EP	EP2006722247A	2006-04-03	EP1755311B1	2009-07-08	GB、FR、DE
	27.1	TW	TW2006118609A	2006-05-25	TWI314414B	2009-09-01	 
	27.1	US	US2006629346A   

11/629,346 	2007-05-07	US20080209532A1	2008-08-28	 
	27.1	WO	WO2006CN595A	2006-04-03	WO2006125359A1	2006-11-30	 
	27.2	CN	CN200510070351A    

200510070351.0	2005-04-30	CN100571134C  

CN 1859093A	2009-12-16	 
	27.2	EP	EP2006741743A	2006-04-27	EP1879324B1	2012-08-01	DE、ES、FR、

GB、IT
	27.2	US	US2007896389A	2007-08-31	US8335487B2	2012-12-18	 
	27.2	WO	WO2006CN822A	2006-04-27	WO2006116921A1	2006-11-09	 
	28	CN	CN200610111254.6	2006-08-17	 	 	 
	28	CN	CN200610141030A	2006-09-28	CN101128049B	2012-07-04	 
	28	EP	EP2007785297A	2007-08-09	EP2056536B1	2012-01-25	FR、DE、GB
	28	WO	WO2007CN2390A	2007-08-09	WO2008022536A1	2008-02-28	 
	29	Argentina	ARP20050103360A	2005-08-11	AR50123A1	2006-09-27	 
	29	BR	BRPI507677A	2005-08-11	BR200507677A	2007-07-17	 
	29	CN	CN200410059164A	2004-08-11	CN1735268A	2006-02-15	 
	29	CN	CN200410059165A	2004-08-11	CN100349473C  

CN 1735232A	2007-11-14  

2006-02-15	 
	29	EP	EP2005774458A	2005-08-11	EP1713241A1	2006-10-18	 
	29	IN	IN2006CN4422A	2006-12-01	IN246930B	2011-03-25	 
	29	Indonesia	IDW-00200602090	2005-08-11	ID0024111 	 	 
	29	RU	RU2006130835A	2005-08-11	RU2370904C2	2009-10-20	 
	29	US	US2006489208A	2006-07-19	US7787608B2	2010-08-31	 
	29	WO	WO2005CN1241A	2005-08-11	WO2006015551A1	2006-02-16	 
	30	CN	CN200710079246A	2007-02-13	CN101247632A	2008-08-20	 
	30	CN	CN200780000599A	2007-11-19	CN101517960A	2009-08-26	 
	30	EP	EP2008101535A	2008-02-12	EP1959632A1	2008-08-20	 
	30	IN	IN5391/DELNP/2009	19 Nov 2007	IN5391/DELNP/2009	 	 
	30	RU	RU2009134133A	2007-11-19	RU2434351C2	2011-11-20	 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 37 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family 

No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP 

Countries 
	30	US	US2009539890A	2009-08-12	US8185105B2	2012-05-22	 
	30	US	US13414770A	2012-03-08	US8417240B2	2013-04-09	 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 38 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family 

No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP 

Countries 
	30	WO	WO2007CN71090A	2007-11-19	WO2008098459A1	2008-08-21	 
	31	CN	CN 200610079107.5	2006-04-29	 	 	 
	31	CN	CN200610099533A	2006-07-28	CN101064661B	2011-08-24	 
	31	CN	CN200780000297A	2007-02-08	CN101317438B	2012-04-25	 
	31	EP	EP2007702308A	2007-02-08	EP1881689B1	2010-06-02	FR、DE、GB
	31	US	US2007881806A	2007-07-27	US20080032686A1	2008-02-07	 
	31	WO	WO2007CN435A	2007-02-08	WO2007124641A1	2007-11-08	 
	32	CN	CN200610035050A	2006-04-18	CN101056452B	2010-05-12	 
	32	CN	CN200680013004A	2006-11-29	CN101167374B	2011-02-09	 
	32	EP	EP20077802A	2007-04-17	EP 1848190A1	2007-10-24	 
	32	US	US2007787527A	2007-04-17	US7764953B2	2010-07-27	 
	32	WO	WO2006CN3214A	2006-11-29	WO2007118380A1	2007-10-25	 
	33	CN	CN200680011755A	2006-11-01	CN101156426B	2011-02-16	 
	33	CN	CN200610057699A	2006-02-24	CN101026653B	2011-08-24	 
	33	EP	EP2007101173A	2007-01-25	EP1826985B1	2009-10-28	FR、DE、GB
	33	US	US2007698891A	2007-01-29	US20070201635A1	2007-08-30	 
	33	WO	WO2006CN2933A	2006-11-01	WO2007095802A1	2007-08-30	 
	34	CN	CN200510114277A	2005-10-21	CN100487788C	2009-05-13	 
	34	EP	EP2006805015A	2006-10-20	EP1950737B1	2010-05-26	DE、GB
	34	US	US2008106693A	2008-04-21	US20080205279A1	2008-08-28	 
	34	WO	WO2006CN2806A	2006-10-20	WO2007045187A1	2007-04-26	 
	35	CN	CN200610140147A	2006-09-30	CN101155148B	2012-02-22	 
	35	EP	EP2007816481A	2007-09-29	EP2068513B1	2010-11-24	DE、IT
	35	US	US2009413015A  

12/413,015  	2009-03-27	US7920579B2	2011-04-05	 
	35	WO	WO2007CN2867A	2007-09-29	WO2008040191A1	2008-04-10	 
	36	CN	CN200710095931A	2007-03-30	CN101277343B	2012-01-04	 
	36	EP	EP2008706632A	2008-02-03	EP2120440B1	2011-10-19	FR、DE、GB
	36	WO	WO2008CN70257A	2008-02-03	WO2008119272A1	2008-10-09	 
	37	CN	CN200610079110A	2006-04-29	CN101064680B	2010-04-21	 
	37	EP	EP2007720936A	2007-04-24	EP2015592B1	2012-07-11	DE、GB
	37	WO	WO2007CN1363A	2007-04-24	WO2007124684A1	2007-11-08	 
	38	CN	CN200510034345A	2005-04-21	CN 1855961 

CN100531267C	2009-08-19	 
	38	EP	EP2006741698A	2006-04-21	EP1874016A1	2008-01-02	 
	38	US	US2007875195A	2007-10-19	US7986775B2	2011-07-26	 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 39 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

	Family 

No.	Country	Application Number	Filing Date	Publication No.	Issue/Pub Date	EP 

Countries 
	38	WO	WO2006CN754A	2006-04-21	WO2006111100A1	2006-10-26	 
	39	CN	CN2001123948A	2001-08-07	CN1400843A	2003-03-05	 
	39	CN	CN2001123948A	2001-08-07	CN1177508C	2004-11-24	 
	39	EP	EP2002719621A	2002-03-29	EP1420605B1	2007-11-28	 
	39	RU	RU2004104321A	2002-03-29	RU2267865C2	2006/1/10	 
	39	US	US2003486322A   

10486322	29 Mar 2002	US7349693B2	2008/3/25	 
	39	WO	WO2002CN219A	2002-03-29	WO2003015437A1	2003-02-20	 

 

 

 

(b)all patents and patent applications
(i) to which any of the Patents directly or indirectly claims priority, (ii) for which any of the Patents directly or indirectly
forms a basis for priority, and/or (iii) that were co-owned applications that
incorporate by reference, or are incorporated by reference into, the Patents;

 

(c)all reissues, reexaminations, extensions,
continuations, continuations in part, continuing prosecution applications, requests for continuing examinations, divisions, registrations
of any item in any of the foregoing categories (a) and (b);

 

(d)all rights to apply in any or all
countries of the world for patents, certificates of invention, utility models, industrial design protections, design patent protections,
or other governmental grants or issuances of any type related to any item in any of the foregoing categories (a) through (c), including,
without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation
Treaty, or any other convention, treaty, agreement, or understanding;

 

(e)all causes of action (whether known
or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of, any of the
Patents and/or any item in any of the foregoing categories (b) through (g), including, without limitation, all causes of action
and other enforcement rights for

 

(1)damages,

(2)injunctive relief, and

(3)any other remedies of any kind

 

for past, current, and future infringement; and

 

(f)all rights to collect royalties and other payments
under or on account of any of the Patents and/or any item in any of the foregoing categories (b) through (h).

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 40 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

Assignor hereby authorizes the respective
patent office or governmental agency in each jurisdiction to issue any and all patents, certificates of invention, utility models
or other governmental grants or issuances that may be granted upon any of the Patent Rights in the name of Assignee, as the assignee
to the entire interest therein.  

 

Assignor will, at the reasonable request
of Assignee and without demanding any further consideration therefore, do all things necessary, proper, or advisable, including
without limitation, the execution, acknowledgment, and recordation of specific assignments, oaths, declarations, and other documents
on a country-by-country basis, to secure to Assignee its rights, title and interest in and to the Patent Rights. 

 

The terms and conditions of this Assignment
of Patent Rights will inure to the benefit of Assignee, its successors, assigns, and other legal representatives and will be binding
upon Assignor, its successors, assigns, and other legal representatives. 

 

REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 41 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

IN WITNESS WHEREOF this Assignment of Patent
Rights is executed at ___________________on May 15, 2013.

 

 

ASSIGNOR:

 

Huawei Technologies Co., Ltd.

 

By:______________________

Name:____________________

Title:_____________________

(Signature MUST be attested)

 

 

 

ATTESTATION OF SIGNATURE PURSUANT
TO 28 U.S.C. § 1746

 

The undersigned witnessed the signature of _________________
to the above Assignment of Patent Rights on behalf of Huawei Technologies Co., Ltd. and makes the following statements:

 

1.I am over the age
of 18 and competent to testify as to the facts in this Attestation block if called upon to do so.

 

2.________________ is
personally known to me (or proved to me on the basis of satisfactory evidence) and appeared before me on _________ __, 2013 to
execute the above Assignment of Patent Rights on behalf of Huawei Technologies Co., Ltd.

 

3.________________ subscribed
to the above Assignment of Patent Rights on behalf of Huawei Technologies Co., Ltd.

 

I declare under penalty
of perjury under the laws of the United States of America that the statements made in the three (3) numbered paragraphs immediately
above are true and correct.

 

EXECUTED on ___________________(date)

________________________________________

Print Name: ________________________

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 42 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

EXHIBIT C

Existing Encumbrances

*

 

 

 

 

 

 

 

 

 

 

 

Any Prior Contests, Oppositions, Reexaminations,
Declaratory Judgment 

Actions, and Other Attacks on the Validity and/or Enforceability of Any

 Transferred Patents

 

 

EP1914937 

EP02719621.1 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 43 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

EXHIBIT D

LIST OF DELIVERABLES

 

Assignor will cause the following to be
delivered to Assignee, or Assignee’s representative, within the time provided in paragraph 3.1 of the attached Patent Purchase
Agreement:

(A)U.S. Patents. For each
item of the Patents that is an issued United States patent, and for each Abandoned Asset that forms the basis for priority for
such issued U.S. patent (whether a patent or similar protection has been issued or granted),

(1) the original

(a) ribbon copy issued by the
United States Patent and Trademark Office,

(b) Assignment Agreement(s),

(2) a copy
of

(a) the Docket,

 

(B)Non-U.S.
for each Asset for which a non-United States patent or similar protection has been issued or granted,

(1) the original ribbon copy or
certificate issued by the applicable government, if available

(2) copy of each pending foreign
application

(3) the Docket,

(4) the original Assignment Agreement(s),

(5) a copy of applicant name change, if necessary, and

(C)Patent Applications: For
each item of the Patents that is a patent application (for example, including the applications that resulted in the issued patents),

(1) a copy of the patent
application, as filed,

(2)if unpublished, a copy
of the filing receipt and the non-publication request, if available,

(3)the original Assignment
Agreement(s),

(4) the Docket,

(5)a copy of invention disclosure
for US application, including the specific conception and/or reduction to practice documents that were provided by inventor(s)
to counsel during the patent prosecution process, or attached to such invention disclosure,

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 44 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

(6) evidence of foreign filing
license (or denial thereof),

(7) the Prosecution History
Files;

 

 

(D)Thorough Search/Declaration. If originals of the Deliverables are not available and delivered to Assignee prior to
Closing, Assignor will cause (i) such originals of the Initial Deliverables to be sent to Assignee or Assignee’s representative
within thirty (30) calendar days after Closing if and after such originals are located.

 

Capitalized terms used in this Exhibit
D are defined in the Patent Purchase Agreement to which this Exhibit D is attached.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 45 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

 

 

EXHIBIT E

COMMON INTEREST AGREEMENT

 

THIS COMMON
INTEREST AGREEMENT ("Agreement") is entered into by and between Huawei Technologies Co., Ltd., a Chinese Corporation,
having offices at Administration Building Huawei Technologies Co., Ltd. Bantian Longgang District, Shenzhen 518129, P. R. China
(“Assignor”), and Inventergy, Inc., a Delaware corporation, having offices at 19925 Stevens Creek Boulevard, Suite
100, Cupertino, California, 95014 United States of America (“Assignee”) (Assignee and Assignor each a “Party”
and together the “Parties”).

 

1. Background.

 

Each of Inventergy and
Huawei have entered into a Patent Rights Assignment Agreement (PRA) in connection with certain patent and other intellectual property
rights of Inventergy and/or Huawei (the "Patent Rights," and matters related to the Patent Rights, the "Patent Matters").

 

The parties share a common
legal interest in upholding the validity and enforceability of the Transferred Patents for purposes of Assignee’s licensing
and enforcement activities.  The parties anticipate that Inventergy will enforce inherent rights of the Patent Rights against
third parties through licensing activities and possibly as well through litigation. The parties have agreed to treat their communications
and those of their counsel relating to the Patent Matters as protected by the common interest doctrine. Furtherance of the Patent
Matters requires the exchange of proprietary documents and information, the joint development of legal strategies and the exchange
of privileged information and attorney work product developed by the parties and their respective counsel.

 

2. Common Interest.

 

In furtherance of their
common interest, the parties may continue to cooperate with each other, to the extent permitted by law, and subject to each party's
discretion, to share information protected by the attorney-client privilege, the work product doctrine, or other applicable privilege
or immunity with respect to the Patent Matters.  Any counsel or consultant retained by a party or their counsel to assist
in the Patent Matters shall be bound by, and entitled to the benefits of this Agreement.  Subject to the PRA, upon further
agreed by parties in writing, the parties and their counsel may continue to exchange privileged and work product information, orally
and in writing, including, without limitation, factual analyses, mental impressions, legal memoranda, source materials, draft legal
documents, evidence of use materials, claims charts, prosecution history files and other information (hereinafter "Common
Interest Materials"). The sole purpose of the exchange of the Common Interest Materials is to support the parties’
common interest with respect to the enforcement for the Patent Matters. Any Common Interest Materials exchanged shall continue
to be protected under all applicable privileges and no such exchange shall constitute a waiver of any applicable privilege or protection.
Nothing in this Agreement requires a party to share information with the other party. Nothing in this Agreement shall constitute
nor cause any obligation or liability to Assignor.

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 46 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

 

Unless otherwise expressly specified under
PRA or further agreed by parties in writing, Assignor and inventors of the Transferred Patents shall not be obligated to assist
in prosecution, maintenance, litigation or licensing of the Transferred Patents or to execute or have executed additional oaths,
declarations or any other assistance after the assignment date.

 

3. Nondisclosure.

 

The parties and their counsel
shall use the Common Interest Materials solely in connection with the Patent Matters and the furtherance of the purposes and interests
of the PRA, and shall take appropriate steps to protect the privileged and confidential nature of the Common Interest Material.
Each party shall notify the other of any request, order and/or directive to produce such privileged documents as soon as practicable
and shall consult with the other party as to the appropriate response. Following such consultation, neither party nor their respective
counsel shall produce privileged documents unless or until required by law as determined by the relevant party's counsel. Except
as herein provided, in the event that either party or its counsel is requested or required in the context of a litigation, governmental,
judicial or regulatory investigation or other similar proceedings (by oral questions, interrogatories, requests for information
or documents, subpoenas, civil investigative demands or similar process) to disclose any Common Interest Materials, the party or
its counsel shall assert all applicable privileges, as determined by its counsel, including, without limitation, the common interest
doctrine, and, as soon as practicable, shall inform the other party and the other party's counsel of the request or requirement
to disclose.

 

4. Relationship; Additions;
Termination.

 

This Agreement
does not by itself create any agency or similar relationship among the parties. Through the term of the agreement between the parties,
or any other agreement requiring confidentiality (whichever term is longer), neither party
nor their respective counsel has the authority to waive any applicable privilege or doctrine on behalf of the other party.

 

Nothing in this Agreement
affects the separate and independent representation of each party by its respective counsel or creates an attorney-client relationship
between the counsel for a party and the other party to this Agreement.

 

This Agreement shall continue
until terminated upon the written request of either party. Upon termination, each party and their respective counsel shall return
any Common Interest Material furnished by the other party, unless otherwise required by law or regulation. Notwithstanding termination,
this Agreement shall continue to protect all Common Interest Materials disclosed prior to termination, including under applicable
attorney client privileges and/or work product doctrine, and sections 3 and 5 shall survive termination of this Agreement.

 

5. General Terms.

 

This Agreement is governed
by the laws of the State of California, without regard to its choice of law principles to the contrary. In the event any provision
of the Agreement is held by any court of competent jurisdiction to be illegal, void or unenforceable, the remaining terms shall
remain in effect. Failure of either party to enforce any provision of this Agreement shall not be deemed a waiver of future enforcement
of that or any other provision.

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 47 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

 

The parties agree that
a breach of this Agreement may result in irreparable injury, that money damages might not be a sufficient remedy and that the disclosing
party shall be entitled to seek equitable relief, including injunctive relief, as a non-exclusive remedy for any such breach.

 

Notices given under this
Agreement shall be given in writing and delivered by messenger or overnight delivery service as set forth below, and shall be deemed
to have been given on the day received:

 

In the case of Inventergy:

 

Wayne P. Sobon, General
Counsel

Inventergy Inc.

19925 Steven Creek Blvd, Suite 100

Cupertino CA 95014-2358

 

In the case of Huawei:

Huawei Technologies Co., Ltd.

Section B, Huawei Industrial Base

Bantian, Longgang District

Shenzhen 518129

P.R.China

 

This Agreement is effective
and binding upon each party to effect the agreements made between Huawei and Inventergy and may be amended only by a writing signed
by or on behalf of each party. This Agreement may be executed in counterparts. Any signature reproduced or transmitted via email
of a .pdf file, photocopy, facsimile or other process of complete and accurate reproduction and transmission shall be considered
an original for purposes of this Agreement.

 

IN WITNESS WHEREOF, both
Huawei and Inventergy have executed this Agreement by their duly authorized representative.

 

	Inventergy, LLC	 	Huawei Technologies Co., Ltd.	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	By	 	 	By	 	 
	 	 	 	 	 	 
	Name     	Joe Beyers	 	Name  	Jianxin Ding (Jason)	 
	 	 	 	 	 	 
	Title       	Inventergy CEO	 	Title    	Director of IP	 
	 	 	 	 	 	 
	Date     	May 15, 2013	 	Date    	May 15, 2013	 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 48 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 49 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

 

EXHIBIT F

ESCROW ADDENDUM TO PATENT PURCHASE AGREEMENT

 

ESCROW AGREEMENT

 

This
Escrow Agreement dated as of May 15, 2013 (the “Agreement”) by and among Inventergy, Inc., a Delaware
corporation, having offices at 19925 Stevens Creek Boulevard, Suite 100, Cupertino, California, 95014 United States of America
(“Buyer”), Huawei Technologies Co., Ltd., a Chinese Corporation, having offices at Administration Building
Huawei Technologies Co., Ltd. Bantian Longgang District, Shenzhen 518129, P. R. China (including any successor thereto, the “Seller”),
and Agent (“Escrow Agent”). Capitalized terms used but not otherwise defined herein will have the meanings
given to such terms in that certain Patent Rights Assignment Agreement dated as of May 15, 2013 (the “PRAA”),
by and between Buyer and the Seller, a copy of which is attached hereto as Exhibit A.

 

RECITALS

 

WHEREAS, the Seller
and Buyer have entered into the PRAA pursuant to which Buyer will purchase the Assigned Patent Rights from the Seller on the terms
and subject to the conditions set forth therein;

 

WHEREAS, the PRAA requires
that Seller, within a certain period as specified in the PRAA, to deliver Executed Assignments (as defined by the PRAA) assigning
the rights to each patent and patent application being assigned by Seller to Buyer to the Escrow Agent (the “Escrow Assignments”),
such Executed Assignments to be held in escrow and disbursed to Buyer at Closing pursuant to the terms and subject to the conditions
set forth in the Patent Purchase Agreement and this Agreement; and

 

WHEREAS, the PRAA requires
that Buyer, at the Closing, upon the terms and subject to the conditions set forth in the Patent Purchase Agreement, deliver $4,000,000
in immediately available funds directly to Seller, under the terms and subject to the conditions set forth in the PRAA; and

 

WHEREAS, pursuant to
the PRAA, Buyer and the Seller agreed to be bound by the terms of this Agreement, in each case to carry out any and all actions
set forth herein, or contemplated by, this Agreement (the Seller, together with the Buyer, the “Escrow Parties”
and each, an “Escrow Party”).

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto, intending to be
legally bound, do hereby covenant and agree as follows:

 

Section 1.Appointment
of Escrow Agent. The Seller and the Buyer hereby appoint Escrow Agent to act as escrow agent in accordance with the terms and
conditions set forth herein, and Escrow Agent hereby accepts such appointment.

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 50 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

  

Section 2.Distribution
of the Escrow Assignments. Escrow Agent shall hold the Escrow Assignments in its possession, provide notice to Buyer and Seller
of receipt of Escrow Assignments that meet the requirements of the PRAA, and then disburse the Escrow Assignments to the Buyer
upon delivery of the Closing Notice by the Buyer and Seller. Notwithstanding the foregoing, if at any time the Escrow Agent shall
receive joint written instructions executed by Buyer and the Seller Escrow Party (“Joint Written Instructions”),
to release the Escrow Assignments in the Escrow Account, then within three (3) Business Days after receipt of such Joint Written
Instructions, the Escrow Agent shall release the Escrow Assignments in accordance with such Joint Written Instructions.

 

Buyer and the Seller Escrow
Party agree that they will endeavor in good faith to execute any joint written notices or instructions in accordance with the terms
of, and at such times as contemplated by, this Agreement.

 

Section 3.Compensation
of Escrow Agent. The Buyer Escrow Party shall pay all fees, costs and expenses of the Escrow Agent for all services rendered
by it hereunder in accordance with Schedule II to this Agreement. The obligations contained in this Section shall survive
the termination of this Agreement and the resignation or removal of Escrow Agent.

 

Section 4.Resignation
or Removal of Escrow Agent. Escrow Agent may resign and be discharged from its duties hereunder at any time by giving written
notice thirty (30) calendar days prior to such resignation to the Escrow Parties as provided in this Section. The Escrow
Parties may remove Escrow Agent at any time by giving written notice signed by each of the Escrow Party’s Authorized Representative
at least thirty (30) calendar days prior to such removal to Escrow Agent. Following such resignation or removal, a successor Escrow
Agent shall be jointly appointed by the Escrow Parties, who shall provide written notice of such to the resigning or removed Escrow
Agent. Such successor Escrow Agent shall become Escrow Agent hereunder, and all Escrow Assignments remaining in Escrow shall be
transferred to it upon the resignation or removal date specified in such notice. If the Escrow Parties are unable to appoint a
successor Escrow Agent within thirty (30) calendar days after such notice, Escrow Agent may petition any court of competent jurisdiction
for the appointment of a successor Escrow Agent or for other appropriate relief. The reasonable costs and expenses (including but
not limited to its attorney fees and expenses) incurred by Escrow Agent in connection with such proceeding shall be split 50/50
by the Escrow Parties. On the resignation/removal date and after receipt of the identity of the successor Escrow Agent, Escrow
Agent shall either deliver and/or disburse the Escrow Assignments then held hereunder to the successor Escrow Agent. Upon its resignation
or removal and delivery of the Escrow Assignments in their entirety as set forth in this Section, Escrow Agent shall be discharged
of and from any and all future obligations arising in connection with the Escrow Assignments or this Agreement.

 

Section 5.Indemnification
of Escrow Agent. The Buyer Escrow Party agrees to indemnify and hold Escrow Agent harmless against any and all liabilities,
losses, claims, damages or expenses, including reasonable attorney’s fees, that Escrow Agent may incur by reason of or based
upon its actions under this Agreement other than as a result of the gross negligence or willful misconduct of Escrow Agent. This
indemnification obligation shall survive the termination of this Agreement and the resignation or removal of Escrow Agent..

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 51 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

  

Section 6.Rights,
Duties and Immunities of Escrow Agent. Acceptance by Escrow Agent of its duties under this Agreement is subject to the following
terms and conditions, which all parties to this Agreement hereby agree shall govern and control the rights, duties and immunities
of Escrow Agent.

 

(a)The
duties and obligations of Escrow Agent shall be determined solely by the express provisions of this Agreement and no duties or
obligations shall be inferred or implied. Escrow Agent shall not be liable except for the performance of such duties and obligations
as are expressly and specifically set out in this Agreement. Escrow Agent shall not be liable for the accuracy of any calculations
made by any Escrow Party or the sufficiency of any funds for any purpose.

 

(b)Escrow
Agent shall not be required to expend or risk any of its own funds or otherwise incur any liability, financial or otherwise, in
the performance of any of its duties hereunder.

 

(c)Escrow
Agent is not a party to, and is not bound by, or required to comply with any agreement or other document out of which this Agreement
may arise. Escrow Agent shall not be required to inquire as to the performance or observation of any obligation, term or condition
under any other agreements or arrangements between the Escrow Parties. Escrow Agent shall be under no liability to any party hereto
by reason of any failure on the part of either Escrow Party or any maker, guarantor, endorser or other signatory of any document
or any other third party to perform, such party’s obligations under any such document. Except for amendments to this Agreement
referred to herein, and except for notifications or instructions to Escrow Agent under this Agreement, Escrow Agent shall not be
obliged to recognize or be chargeable with knowledge of any of the terms or conditions of any agreement between the Escrow Parties,
notwithstanding that references thereto may be made herein and whether or not it has knowledge thereof.

 

(d)Escrow
Agent shall not have any responsibility to determine the authenticity or validity of any notice, direction, instruction, instrument,
document or other items delivered to it by any party, or for the identity, authority or rights of persons executing or delivering
any such notice, direction, instruction, instrument, document, or other items delivered to it by such party or parties. Escrow
Agent is authorized to comply with and rely upon any notice, direction, instruction or other communication reasonably believed
by it to have been sent or given by either Escrow Party and, in the absence of willful misconduct or gross negligence, shall be
fully protected in acting in accordance with such written direction or instructions given to it under, or pursuant to, this Agreement.

 

(e)Escrow
Agent shall not be bound by any waiver, modification, termination or rescission of this Agreement or any of the terms hereof, unless
evidenced in writing and delivered to Escrow Agent signed by each party’s Authorized Representative and, if the duties or
rights of Escrow Agent are affected, unless it shall give its prior written consent thereto. No person, firm or corporation will
be recognized by Escrow Agent as a successor or assignee of either Escrow Party until there shall be presented to Escrow Agent
evidence satisfactory to it of such succession or assignment. This Agreement shall not be deemed to create a fiduciary relationship
among the parties hereto under state or federal law.

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 52 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

  

(f)If
at any time Escrow Agent is served with any judicial or administrative order, judgment, decree, writ or other form of judicial
or administrative process which in any way affects the Escrow Assigments (including but not limited to orders of attachment or
any other forms of levies or injunctions or stays relating to the transfer of the Escrow Assignments), Escrow Agent is authorized
to comply therewith in any manner as it or its legal counsel of its own choosing deems appropriate; and if Escrow Agent complies
with any such judicial or administrative order, judgment, decree, writ or other form of judicial or administrative process, Escrow
Agent shall not be liable to any of the parties hereto or to any other person or entity even though such order, judgment, decree,
writ or process may be subsequently modified or vacated or otherwise determined to have been without legal force or effect.

 

(g)Escrow
Agent shall not be liable for any action taken or omitted or for any loss or damage resulting from its actions or its performance
of its duties hereunder in the absence of gross negligence or willful misconduct on its part, provided that Escrow Agent acts in
accordance with this Agreement. In no event shall Escrow Agent be liable (i) for acting in accordance with or relying upon any
instruction, notice, demand, certificate or document from either Escrow Party, or any entity acting on behalf of either, (ii) for
any consequential, punitive or special damages, (iii) for the acts or omissions of its nominees, designees, subagents or subcustodians,
or (iv) for an amount in excess of the value of the Escrow Assignments, valued as of the date of loss.

 

(h)In
the event of any ambiguity or uncertainty hereunder or in any notice or other communication received by Escrow Agent hereunder,
Escrow Agent is hereby authorized by the Escrow Parties to refrain from taking any action other than to retain possession of the
Escrow Assignments, unless Escrow Agent receives written instructions, signed by an Authorized Representative of both Escrow Parties
which eliminates such ambiguity or uncertainty.

 

(i)Escrow
Agent may consult with legal counsel of its own choosing (the fees of which shall be indemnifiable expenses pursuant to Section
9) as to any matter relating to this Agreement and Escrow Agent shall incur no liability and shall be fully protected in respect
of any action taken, omitted or suffered by it in good faith in accordance with the advice or opinion of such counsel.

 

(j)In
the event of any dispute or conflicting claim with respect to the payment, ownership or right of possession of the Escrow Account,
Escrow Agent shall be entitled, in its sole discretion, to refuse to comply with any and all claims, demands or instructions. Escrow
Agent is authorized and directed to retain in its possession, without liability to anyone, except for its own gross negligence
or willful misconduct, all or any part of the Escrow Assignments until such dispute shall have been settled either by mutual agreement
of the parties concerned or by final order, decree or judgment of a court or other tribunal of competent jurisdiction in the United
States of America (as notified to Escrow Agent in writing by the parties to the dispute or their authorized representatives and
setting forth the resolution of the dispute). Escrow Agent shall be under no duty whatsoever to institute, defend or partake in
such proceedings. The rights of Escrow Agent under this paragraph are in addition to all other rights which it may have by law
or otherwise including, without limitation, the right to file an action in interpleader.

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 53 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

(k)Escrow
Agent shall not incur liability for not performing any act or not fulfilling any duty, obligation or responsibility hereunder by
reason of any occurrence beyond the foreseeable control of Escrow Agent (including but not limited to any act or provision of any
present or future law or regulation or governmental authority, any act of God or war, terrorism or the unavailability of the Federal
Reserve Bank or other wire or communication facility).

 

(l)When
Escrow Agent acts on any communication (including, but not limited to, communication with respect to the delivery of securities
or the wire transfer of funds) sent by electronic transmission, Escrow Agent, absent gross negligence or willful misconduct, shall
not be responsible or liable in the event such communication is not an authorized or authentic communication of the party involved
or is not in the form the party involved sent or intended to send (whether due to fraud, distortion or otherwise). Escrow Agent
shall not be liable for any losses, costs or expenses arising directly or indirectly from Escrow Agent’s reliance upon and
compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. 
Buyer or the Seller Escrow Party, as the case may be, absent gross negligence or willful misconduct, agrees to assume all risks
arising out of the use of such electronic transmission to submit instructions and directions to Escrow Agent, including without
limitation the risk of Escrow Agent acting on unauthorized instructions, and the risk or interception and misuse by third parties.

 

Section 7.Notices.
All notices, consents, requests, instructions, approvals and other communications provided for in this Agreement shall be in writing,
signed by the proper party’s Authorized Representative and sent by: (i) personal delivery, overnight delivery by a recognized
courier or delivery service, (ii) mailed by registered or certified mail, return receipt requested, postage prepaid, or (iii) electronic
transmission, which includes fax machine, email with an imaged or scanned attachment (such as a .pdf) or other similar electronic
transmission, (receipt confirmed); and shall become effective when delivered to the addresses noted below or such other address
as may be substituted therefor by written notification by the proper party’s Authorized Representative. Notices to Escrow
Agent shall be deemed to be effective when actually received by Escrow Agent’s Corporate Trust Department.

 

If to Buyer, to:

 

Inventergy,
Inc.

19925 Stevens
Creek Boulevard

Cupertino,
CA 95014

Attention:
Joseph Beyers

Email: Joe@Inventergy.com

 

If to the Seller, to:

 

Huawei Technologies Co., Ltd.

Section B, Huawei Industrial
Base

Bantian, Longgang District

Shenzhen 518129

P.R.China

 

Attention:
Ren Zhenwei(Wills)

Email: *

 

If to Escrow Agent,
to:

 

[ ]

Attn:

Fax:

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 54 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

  

Section 8.Termination.
This Agreement shall terminate on the date on which all the Escrow Assignments have been disbursed or returned pursuant to Section
6 or Section 8 of this Agreement.

 

Section 9.Continuing
Obligations. The obligations under Sections 6, 7, 8, 9 and 10 hereof shall survive the resignation
or removal of Escrow Agent, the termination of this Agreement and the payment of all amounts hereunder.

 

Section 10.Inconsistent
Provisions. The Escrow Parties agree that to the extent that the provisions of any other agreement relating to the Escrow Assignments
are inconsistent with the terms of this Agreement, the terms of this Agreement shall control.  

 

Section 11.Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of Hong Kong.  Escrow Agent shall not
be deemed to be transacting a banking or trust businesses or otherwise doing business in Hong Kong for any purpose whatsoever solely
by virtue of the choice of Hong Kong law to govern the terms of this Agreement.

 

Section 12.Counterparts.
This Agreement may be executed in any number of counterparts each of which shall be deemed to be an original, and all of which
together shall constitute but one and the same instrument. Executed copies of this Agreement delivered pursuant to Section 11
above shall be as effective as an original to bind the parties.

 

Section 13.Severability.
The invalidity, illegality or unenforceability of any provision of this Agreement shall in no way affect the validity, legality
or enforceability of any other provision; and if any provision is held to be unenforceable as a matter of law, the other provisions
shall not be affected thereby and shall remain in full force and effect.

 

Section 14.Authorized
Representative. The Escrow Parties hereby identify to Escrow Agent the officers, employees or agents designated on Schedule
I attached hereto as an Authorized Representative with respect to any notice, certificate, instrument, demand, request, direction,
instruction, waiver, receipt, consent or other document or communication required or permitted to be furnished to Escrow Agent.
Such Schedule I may be amended and updated by written notice to Escrow Agent with a copy to the other party to this Agreement
provided that failure to furnish such copy shall not affect the validity of such notice to Escrow Agent. Escrow Agent shall be
entitled to rely on such original or amended Schedule I with respect to any party until a new Schedule I is furnished
by such party to Escrow Agent.

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 55 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

Section 15.Jurisdiction
and Choice of Law. This Agreement shall be governed by the laws of Hong Kong, without giving effect to principles of conflicts
of law. All disputes, controversies and differences between the Parties arising out of or relating to this Agreement shall be settled
amicably through negotiations in good faith. If any dispute or controversy cannot be settled amicably through negotiations within
a thirty (30) calendar day period, it shall be submitted to Hong Kong International Arbitration Centre. The award of the arbitration
shall be final and binding upon the Parties. EACH PARTY HEREBY WAIVES TRIAL BY JURY IN ANY ACTION OR PROCEEDING RELATING TO THIS
AGREEMENT.

 

Section 16.Miscellaneous.

 

(a)The rights and
remedies conferred upon the parties hereto shall be cumulative, and the exercise or waiver of any such right or remedy shall not
preclude or inhibit the exercise of any additional rights or remedies. The waiver of any right or remedy hereunder shall not preclude
the subsequent exercise of such right or remedy.

 

(b)This Agreement
is for the exclusive benefit of the parties hereto and their respective successors hereunder, and shall not be deemed to give,
either express or implied, any legal or equitable right, remedy, or claim to any other entity or person whatsoever.

 

(c)Each party hereby
represents and warrants (i) that this Agreement has been duly authorized, executed and delivered on its behalf and constitutes
its legal, valid and binding obligation and (ii) that, to its knowledge, the execution, delivery and performance of this Agreement
by the parties hereto does not violate any applicable law or regulation.

 

(d)The headings contained
in this Agreement are for convenience of reference only and shall have no effect on the interpretation or operation hereof.

 

(e)Except as otherwise
permitted herein, this Escrow Agreement may be modified only by a written amendment signed by Buyer’s and Seller’s
Escrow Party’s Authorized Representative and Escrow Agent, and no waiver of any provision hereof will be effective unless
expressed in a writing signed by Buyer’s and the Seller Escrow Party’s Authorized Representative and Escrow Agent.

 

(f)No party may assign
any of its rights or obligations under this Escrow Agreement without the written consent of the other parties.

  

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 56 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

(g)Any entity into
which Escrow Agent may be merged or converted or with which it may be consolidated, or any entity resulting from any merger, conversion
or consolidation to which Escrow Agent will be a party, or any entity succeeding to all or substantially all the business of Escrow
Agent will be the successor of Escrow Agent hereunder without the execution or filing of any paper with any party hereto or any
further act on the part of any of the parties hereto except where an instrument of transfer or assignment is required by law to
effect such succession, anything herein to the contrary notwithstanding.

 

 

 

[Signature Page to Follow]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 57 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the day and year first above written.

 

  

	 	 	 	 
	 	 	 	 
	 	By  	 	 
	 	       	     Name:	 
	 	       	     Title:	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By  	 	 
	 	      	     Name:	 
	 	      	     Title:	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	as Escrow Agent	 
	 	 	 	 
	 	 	 	 
	 	By 		 
	 	      	     Name:	 
	 	      	     Title:	 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 58 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

Schedule
I

 

ESCROW ACCOUNT SIGNING AUTHORITY

 

 

Authorized Representative(s) of Buyer

 

The undersigned certifies that each of
the individuals listed below is an Authorized Representative of Buyer with respect to any instruction or other action to be taken
in connection with the Escrow Agreement and [ ] shall be entitled to rely on such list until a new list is furnished to [ ].

 

	
        Signature: _________________________

        Print: Joseph W. Beyers

        Title: CEO, Authorized Person

        Phone: 408-973-7896

        Fax:

        Email: Joe@Inventergy.com
	
        Signature: _________________________

        Print: Wayne P. Sobon

        Title: General Counsel, Authorized Person

        Phone: 408-973-7896

        Fax:

        Email: Wayne@Inventergy.com

 

The undersigned further certifies that
he or she is duly authorized to sign this Escrow Account Signing Authority.

 

 

Signature: _________________________ **

Name:

Its:

Date:

 

**To be signed by corporate
secretary/assistant secretary on the same copy as the Authorized Representative(s). When the secretary is among those authorized
above, the president must sign in the additional signature space provided below. For entities other than corporations, an authorized
signatory not signing above should sign this Escrow Account Signing Authority.

 

(Additional signature, if required)

 

 

Signature: _________________________

Name:

Its:

Date:

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 59 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

Authorized Representative(s) of the
Seller

 

The undersigned certifies that each of
the individuals listed below is an Authorized Representative of the Seller with respect to any instruction or other action to be
taken in connection with the Escrow Agreement and [ ] shall be entitled to rely on such list until a new list is furnished to [
].

 

	
        Signature: _________________________

        Print: Ding Jianxin

        Title: Director of IP

        Phone:

        Fax:

        Email:
	
        Signature: _________________________

        Print: Ren Zhenwei

        Title: IP Counsel

        Phone:

        Fax:

        Email:

 

The undersigned further certifies that
he or she is duly authorized to sign this Escrow Account Signing Authority.

 

 

Signature: _________________________ **

Name:

Its:

Date:

 

**To be signed by corporate
secretary/assistant secretary on the same copy as the Authorized Representative(s). When the secretary is among those authorized
above, the president must sign in the additional signature space provided below. For entities other than corporations, an authorized
signatory not signing above should sign this Escrow Account Signing Authority.

 

(Additional signature, if required)

 

 

Signature: _________________________

Name:

Its:

Date:

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 60 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

PAGE INTENTIONALLY LEFT BLANK

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 61 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

Schedule
II

 

ESCROW AGENT COMPENSATION

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

 

    	 	Huawei Inventergy Confidential	 62 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 PAGE INTENTIONALLY LEFT BLANK

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 63 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

 

EXHIBIT G

*

 

*

 

 

 

 

*The * shall include its current, further
*, *, * and *, or its *.

 

“*”
shall have the meaning of *.

 

REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	 64 / 65

    	 

    

 

		CONFIDENTIAL
    TREATMENT REQUESTED	 

EXHIBIT H

 

 

*

 

 

*

 

 

*The * shall include *, *, * (as defined
in Exhibit G), *, *.

 

List A

 

*

 

REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK

 

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are
designated with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

 

    	 	Huawei Inventergy Confidential	65 / 65CONFIDENTIAL TREATMENT REQUESTED

 

 

PATENT PURCHASE AGREEMENT

 

This PATENT PURCHASE
AGREEMENT (hereinafter referred to as “Agreement”) is entered into and effective as of October 21, 2013 (hereinafter
referred to as “Effective Date”), by and between Panasonic Corporation, a Japanese corporation having a principal
place of business at 1006 Oaza Kadoma, Kadoma-shi, Osaka 571-8501, Japan (hereinafter referred to as “Seller”)
and Inventergy, Inc., a Delaware corporation with a business address at 19925 Stevens Creek Boulevard, Suite 100, Cupertino, California
95014, USA (hereinafter referred to as “Buyer”). Hereinafter, Seller and Buyer are each referred to as a “Party”,
and collectively as the “Parties”.

 

RECITALS

 

WHEREAS, Panasonic
owns certain Patent Assets (as defined below in Section 1) and now desires to assign and transfer to Buyer its right, title and
interest in and to the Patent Assets; and

 

WHEREAS, Buyer
wishes to purchase from Seller the right, title, and interest in such Patent Assets, with a grant-back license from Buyer to Seller
of such Patent Assets;

 

NOW THEREFORE,
in consideration of the foregoing and of the mutual promises, covenants and agreements contained in this Agreement, the Parties
hereby agree as follows:

 

 

SECTION 1

DEFINITIONS

 

(a) “Affiliate(s)”
shall mean any legally recognizable entity which is Controlled by Party, or which Controls the Party, or which is in common Control
with Party. An entity shall be deemed as Party’s Affiliate(s) only so long as such Control exists.

 

(b) “Agreement”
has the meaning defined in the first paragraph of this Agreement.

 

(c) “Appendix
Patents” has the meaning defined in Section 1(v) of this Agreement.

 

(d) “Buyer”
has the meaning defined in the first paragraph of this Agreement.

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	1

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

  

 

(e) “Continuing
Licenses” has the meaning defined in Section 8.4 of this Agreement.

 

(f) “Control”
means direct or indirect (i) ownership of more than fifty percent (50%) of the outstanding shares representing the right to
vote for members of the board of directors or other managing officers of such entity, or (ii) for an entity that does not have
outstanding shares, more than fifty percent (50%) of the ownership interest representing the right to make decisions for such
entity.

 

(g) “Deducted
Costs” has the meaning defined in Section 1 (q) of this Agreement.

 

(h) “Effective
Date” has the meaning defined in the first paragraph of this Agreement..

 

(i)
“Encumbrances/Prior Licenses” has the meaning defined in Section 8.3 of this Agreement.

 

(j)
“Governmental Entity” shall mean any court, administrative agency or commission or other federal, state, county,
local or foreign governmental authority, instrumentality, agency commission or subdivision thereof, including but not limited to
the U.S. Patent and Trademark Office, the European Patent Office and the Japan Patent Office.

 

(k) “Grant-Back”
has the meaning defined in Section 2.5 of this Agreement.

 

(l) “Gross
Revenue” shall mean total income and revenue obtained by Buyer in relation to Buyer’s commercialization activities
for Patent Assets, including but not limited to the licensing, selling or other monetization of any of the Patent Assets.

 

(m) “Guaranteed
Payments” has the meaning defined in Section 3.4 of this Agreement.

 

(n) “Guaranteed
Payment Date” has the meaning defined in Section 3.4 of this Agreement.

 

(o) “Licensed
Products” means any product, process, method or service which would infringe or prima facie infringe, directly or indirectly,
any claim of the Patent Assets.

 

(p) “LICENSEE”
has the meaning defined in Section 8.3 (b) of this Agreement.

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	2

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

(q) “Net
Revenue” shall mean all proceeds, income, payments and revenues obtained (actually received as cash) by Buyer during
the term of this Agreement and/or after its termination in relation to Buyer’s commercialization activities for Patent Assets,
including but not limited to the licensing, selling, or other monetization of any of the Patent Assets, after deducting from Gross
Revenue: (1) any governmental taxes including withholding taxes, (2) any reimbursement to its licensees due to overpayments from
such licensees to Buyer; and (3) any and all accrued litigation related third party invoiced expenses (preparation, execution or
contingency fee payments) (hereinafter, such deducted costs shall be referred to as “Deducted Costs”). In any
event, the accrued Deducted Costs deducted from Gross Revenue to yield a particular quarterly Net Revenue shall not exceed more
than * percent (*%) of the Gross Revenue applicable to that particular quarterly Net Revenue, but any excess accrued Deducted Costs
may be applied to subsequent Net Revenue. For the avoidance of doubt, Buyer is solely liable for any third party litigation related
costs and negotiation related costs. None of Buyer’s internal costs of operation, including but not limited to any costs
associated with the commercialization of the Patent Assets and Buyer’s internal costs associated with litigation in support
of commercialization efforts, shall be deducted in Net Revenue calculations. For the avoidance of doubt, Net Revenue does not encompass
any receipts by Buyer due to general corporate financing, whether equity or debt, or money or other value received as part of changes
of control, mergers or acquisitions of substantially all the assets of Buyer, its successor or assigns, or similar general corporate
transactions.

 

(r) “Net Revenue
Share” has the meaning defined in Section 3.2 of this Agreement.

 

(s) “New Owner”
has the meaning defined in Section 3.4 of this Agreement.

 

(t) “Parties”
has the meaning defined in the first paragraph of this Agreement.

 

(u) “Party”
has the meaning defined in the first paragraph of this Agreement.

 

(v)
“Patent Assets” shall mean those patents and pending patent applications of Seller as listed in Appendix
A (hereinafter, referred to as “Appendix Patents”) and all of their related families, including all counterpart
patents and applications, in any geography or jurisdiction, pending patent applications and lapsed or otherwise abandoned patents
or patent applications which: (a) claim priority to the Appendix Patents, or (b) to which the Appendix Patents claimed priority
(hereinafter, referred to as “Priority Patents”), or (c) which claim priority to the Priority Patents (“Subsequent
Patents”). For the purpose of clarity, any patents or patent applications which are subject to a terminal disclaimer
with regard to Appendix Patents, Priority Patents or Subsequent Patents are included in Patent Assets. For the avoidance of doubt,
Patent Assets includes any and all continuations, divisionals, reissues, reexaminations, or other similar refiling or additional
filing of a patent application for claims based upon embodiments contained in the specifications of any of the patents and patent
applications listed in Appendix A and (ii) rights to apply in any or all countries of the world for patents, certificates
of invention or utility models related to any of the patents and patent applications listed in Appendix A.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	3

    	 

    

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

(w)
“Payment Date” shall mean the actual day, no later than thirty (30) calendar days from the Effective Date, on
which Buyer effects transfer of the Up-front Payment set forth in Section 3.1 hereof to Seller.

 

(x) “Person”
means any individual, corporation, partnership, firm, association, trust, unincorporated organization or other entity, as well
as any syndicate or group of any of the foregoing.

 

(y) “Priority
Patents” has the meaning defined in Section 1 (v) of this Agreement.

 

(z) “Prior
Renewable Licenses” has the meaning defined in Section 8.3 (d) of this Agreement.

 

(aa) “Prior
SiproLAB Licensees” has the meaning defined in Section 8.3 (c) of this Agreement.

 

(bb) “Purpose
Related to Weapons” has the meaning defined in Section 9.14 of this Agreement.

 

(cc) “*”
has the meaning defined in Section 8.3 (b) of this Agreement.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	4

    	 

    

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

(dd) “Quarterly
Payment Date” shall mean a day no later than sixty (60) calendar days after each end of the quarter of the calendar year.

 

(ee) “Renewing
Licensees” has the meaning defined in Section 8.3 (d) of this Agreement.

 

(ff) “Seller”
has the meaning defined in the first paragraph of this Agreement.

 

(gg) “Settled
Third Party” has the meaning defined in Section 4.3 (a) of this Agreement.

 

(hh)
“SiproLAB License(s)” has the meaning defined in Section 8.3 (c) of this Agreement.

 

(ii) “SiproLAB
Patents” has the meaning defined in Section 8.3 (c) of this Agreement.

 

(jj) “Standstill
Agreement” has the meaning defined in Section 9.15 of this Agreement. ]

 

(kk) “Subsequent
Patents” has the meaning defined in Section 1 (v) of this Agreement.

 

(ll) “Transfer
Documents” mean patent transfer documents, in the form of Appendix B or in a form drafted by Buyer and approved
by Seller, suitable for filing with the relevant Governmental Entity in each jurisdiction where the Patent Assets issue from or
have been filed, as the case may be, in each case to record the change of ownership of the Patent Assets from Seller to Buyer.

 

(mm) “Transferees”
has the meaning defined in Section 8.4 of this Agreement.

 

(nn) “Trigger
Date” has the meaning defined in Section 4.2 of this Agreement.

 

(oo) “Up-front
Payment” has the meaning defined in Section 3.1 of this Agreement.

 

(pp) “SSO”
shall mean any standard setting organization or other entity that seeks to develop or establish technology standards including,
but not limited to, ETSI, and ARIB.

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	5

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

(qq)
“SSO Commitments” shall mean the covenants, promises, declarations and other undertakings, such as Fair, Reasonable,
and Non-Discriminatory (FRAND) commitment, made or committed to by Seller to any SSO relating to any of the Patent Assets, whether
explicit or implicit, pursuant to the membership agreement, bylaws or policies of such SSO.

 

 

SECTION 2

TRANSFER OF PATENTS AND LICENSE OF PATENT
PORTFOLIO

 

		2.1	Assignment of Patent Assets. In consideration of, and subject to, the payments set forth
in Section 3 hereof, Seller hereby irrevocably sells, transfers, conveys and assigns to Buyer, and Buyer shall acquire from Seller
the right, title and interest in and to all the Patent Assets. Seller further transfers and assigns to Buyer all causes of action,
rights, and remedies arising under any such Patent Assets prior to, on or after the Effective Date of this Agreement and all claims
for damages by reason of past, present or future infringement or other unauthorized use of such Patent Assets. The sale, assignment,
transfer and conveyance in this Section 2.1 is subject to (a) any Encumbrances/Prior Licenses provided in Section 8.3, (b) the
Grant-Back provided in Section 2.5, (c) all SSO Commitments, and (d) Panasonic’s reservation of the right to collect royalties
for Encumbrances/Prior Licenses as described in Section 8.3 (c).

 

		2.2	Delivery and Recordation.

 

		(a)	Transfer Documents. Seller shall execute and deliver to Buyer the Transfer Documents via
mail no later than fourteen (14) days after receipt of the Up-Front Payment. For the sake of clarity, the Parties agree and understand
that Appendix B is only for the purpose of recording a conveyance instrument with relevant patent offices, and under no
circumstance shall be used to create or change in any way the rights and obligations of either Parties set forth in this Agreement,
and that in all events the terms and conditions of this Agreement shall control.

 

		(b)	Additional Documents. After the receipt of the Up-Front Payment, and within a reasonable
time after the request of Buyer and at Buyer’s expense, Seller shall execute all documents and instruments prepared by the
Buyer, and shall do all lawful acts, in each case as is necessary to prefect Buyer’s right, title and interest in and to
such Patent Assets and recordation thereof, provided that Buyer shall provide Seller with any documents requiring Seller’s
signature, suitable for recording, having terms and conditions acceptable to Seller and substantially similar to Appendix B
except for any additional or different terms and conditions that would be legally necessary in patent assignments in the subject
jurisdiction. Buyer shall provide Seller with an English translation of each such document (except documents written in Japanese)
concurrently therewith.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	6

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		(c)	Fee
for Recordation. Except as expressly set forth in this Agreement, Buyer shall be solely responsible for all actions and all
costs whatsoever, including but not limited to taxes, attorney’s fees and patent office fees in any jurisdiction, associated
with the perfection of the Buyer’s right, title and interest in and to each Patent Assets and recordation thereof.
Buyer agrees to compensate Seller for any out-of-pocket costs in relation
to such recordation, if any.

 

		2.3	Modifications. To the extent that either Party discovers any patent should be included or
upon finding any typographical errors or omissions on Appendix A (including pending, granted or lapsed family members of
the Patent Assets as defined by Section 1 (v)), upon the consent of both Parties, Appendix A shall be amended accordingly
to include such patent or fix such typographical errors or omissions, without further consideration, and Appendix A as amended
shall become part of this Agreement.

 

		2.4	Information Necessary for Reward. Buyer shall provide Seller with any information which
is necessary for Seller to perform its legal or contractual obligations to the inventor(s) of the Patent Assets (i.e., reasonable
reward) which arise in connection with the assignment of the Patent Assets. For the avoidance of doubt, Buyer is not responsible
for any payment or out-of-pocket expenses associated with any such “reasonable reward” to inventor(s), or other similar
inventor-compensation in any country.

 

		2.5	Grant-Back.

		(a)	Buyer, on behalf of itself and its Affiliates, grants
to Seller and its Affiliates and subcontractors, a non-exclusive, non-assignable, non-transferable (except as expressly set forth
in this Section 2.5 below), non-sub-licensable (except as expressly set forth in this Section 2.5 below), perpetual (both prospective
and retroactive), irrevocable, worldwide, fully paid-up and royalty-free license and release (hereinafter referred to as “Grant-Back”)
under all current and future issued Patent Assets to make, have made, use, offer to sell, sell, lease, import, export or otherwise
dispose of any Licensed Products. The license granted to Seller shall include the right to grant sublicenses of the same or lesser
scope to any third party as required of the Seller under the Encumbrances/Prior Licenses as described in Sections 8.3 (c) and
8.3 (d). In the event of any change of control or sale of any of Seller’s and/or its Affiliate’s business or assets
which enjoy this Grant-Back, the Grant-Back hereunder shall extend for the benefit of the acquirer and continue in effect as to
any of that buyer’s products and services which are substantially the same as the Licensed Products and/or any derivative
products and/or services thereof of such sold business as at the time of the change of control or sale. Nothing in this Agreement
shall be deemed to obligate Buyer to file, maintain, or prosecute any patent or patent application included in or with respect
to the Patent Assets.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	7

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		(b)	Seller reserves and retains, for the benefit of itself
and its Affiliates and its and their successors and assigns, * as described in Section 8.3 (c).

 

 

SECTION 3

CONSIDERATION

 

		3.1	Up-front Payment. As consideration for the Patent Assets and Seller’s full performance
of its obligations under this Agreement, Buyer shall pay Seller * (*) * US Dollars as an up-front, one-time, non-refundable payment
(hereinafter referred to as “Up-front Payment”) subject to any required withholding taxes per Section 3.5, to
be paid by telegraphic transfer to the bank account specified in Section 3.3 hereof by the Payment Date.

 

		3.2	Net Revenue Share. Buyer shall pay to Seller * percent (*%) of Net Revenue as a net revenue
share (hereinafter referred to as “Net Revenue Share”) quarterly by the Quarterly Payment Date subject to any
required withholding taxes per Section 3.5, to be paid by telegraphic transfer to the bank account specified in Section 3.3 hereof.
No later than thirty (30) days after the end of March, June, September, and December of any calendar year during which Net Revenue
is obtained by the Buyer, Buyer shall report the Net Revenue Share and related evidence information thereto, including but not
limited to, the Gross Revenue, the Deducted Costs, the Net Revenue Share and the list of Patent Assets which were used for Buyer’s
commercialization activities, which support the amount of the Net Revenue Share to Seller.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	8

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		3.3	Payment Method. Any payment due from Buyer to Seller under this Agreement shall be in United
States Dollars (US Dollars) to the following bank account, and notice of the payment shall be sent on the date of the payment by
buyer to Seller’s address as set forth in Section 9:

 

	 	
        Bank Name: *

        Corporation Branch Name: *

        Bank Address: *

        Accountholder: *

        Account Number: *

        Swift Code: *

 

		3.4	Guaranteed Payments. Buyer shall pay Seller a minimum of * (*) million US Dollars during
the * (*) * (beginning *), * (*) million US Dollars during the * (*) *, and * (*) * US Dollars during the * (*) * following the
* as a * (“Guaranteed Payments”) by or before the * for the * (*) * of such * (hereinafter referred to as “Guaranteed
Payment Date”). In the event that the total accrued amount of Net Revenue Share of * (*) and * (*) * for each * (*),
* (*), and * (*) * is less than the respective Guaranteed Payments for that *, Buyer shall pay the difference between such total
accrued amount of Net Revenue Share of the * (*) and * (*)* and the Guaranteed Payments of such * in order to satisfy the Guaranteed
Payment of such * by the Guaranteed Payment Date. For purpose of clarity, in the event Buyer paid to Seller the difference between
such total accrued amount of Net Revenue Share of the * (*) and * (*)* and the Guaranteed Payments due in such *, the Net Revenue
Share of the * (*) and * (*)* due in such * shall be reduced in aggregate by the amount of such difference paid by Buyer. For the
avoidance of doubt, in the event the total accrued amount of Net Revenue Share of * (*) and * (*)* for the * (*),* (*), and * (*)*is
equal to or more than the respective Guaranteed Payments for that *, Buyer is not required to make any additional Guaranteed Payments
for that * in order to satisfy its Guaranteed Payments obligation. Buyer agrees that the Guaranteed Payments shall be due irrespective
of any change in the status of the Patent Assets or the rights Buyer enjoys with respect thereto, including but not limited to
any transfer, assignment, or abandonment of any right, title and/or interest in and to the Patent Assets by Buyer during the term
of this Agreement, except for termination of this Agreement pursuant to Section 4.2 hereof. For the purpose of clarity, the sale
of any or all the Patent Assets to a new owner (“New Owner”) on or prior to the end of the * (*)* does not relieve
Buyer of its obligation to pay Seller any outstanding balance(s) of the Guaranteed Payments and of any further Net Revenue Share
payments for, e.g., installment sale payments by a New Owner paid to Buyer as part of such sale (to the extent they exceed the
Guaranteed Payments), but it does relieve any such New Owner of any obligations to pay any Net Revenue Share or Guaranteed Payments
to Seller.. In such an event of a sale of any or all of the Patent Assets on or prior to the end of the * (*)*, Buyer shall still
pay the Guaranteed Payments due in the * by or before the end of that respective *
(s) (i.e., if a sale of all the Patent Asserts occurs in the * (*)*, Buyer shall still pay to Seller the Guaranteed Payments of
* (*)* US Dollars in the * (*)*,* (*)* US Dollars in the * (*)* and * (*)* US Dollars in the * (*)*.

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	9

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		3.5	Taxes.Buyer is responsible to pay in the
first instance for all applicable and not exempt withholding or similar taxes with regard to the Patent Assets or the future revenue
share reflecting income or other taxes. If so required by applicable law and not exempt subject to applicable bilateral tax treaties
(e.g. tax treaties between the US and Japan), Buyer shall withhold the amount of taxes levied on Up-front Payment, Guaranteed
Payments, and Net Revenue Share stated above, and shall promptly make payment of the withheld amount to the appropriate tax authorities
and shall transmit to Seller both the balance of the Up-front Payment, Guaranteed Payments, and/or Net Revenue Share less such
taxes, as well as official tax receipts or other evidence issued by said appropriate tax authorities sufficient to enable Seller
to support a claim for tax credit in respect to such withheld taxes so paid by Buyer. Buyer shall be responsible for taking all
appropriate or required procedures therefore and consistent with the Tax Treaty between the United States of America and Japan,
including but not limited to obtaining and submitting any necessary documents, such as Form W-8BEN to the relevant tax authorities
as may be needed to avoid such deduction or withholding. Upon Buyer’s request, Seller shall cooperate in providing such
any necessary documents or related information. In the event Buyer should receive a rebate, refund, credit, or other reimbursement
of taxes paid above, Buyer shall promptly notify and pay to Seller any such amount received. Buyer shall timely and fully cooperate
with Seller in preparation of any documentation required by the appropriate tax authorities, including providing Buyer with a
signed original of any application form and/or attachments as required by the appropriate tax authorities. Parties will agree
upon a reasonable mechanism for initial and ongoing payments, net of any required withholding taxes, and agree to work collaboratively
to minimize any such required taxes. Buyer is responsible for its own liability for income tax on income received from the monetization
of the Patent Assets.

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	10

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		3.6	Failure of Payment. Notwithstanding anything herein to the contrary, if Buyer fails to
                                                          make the payments set forth in Section 3.1, 3.2, and/or 3.4 by the respective Payment Date, Quarterly Payment Date, and/or
                                                          Guaranteed Payment Date, Seller will charge a late fee of the lesser of a)  * and a * percent (*%) per month and b) the
                                                          maximum rate allowable by applicable law on any balance remaining unpaid for more than thirty (30) days from the each payment
                                                          due date stipulated in this Agreement, and Buyer shall pay such late fee.

 

		3.7	Costs and Expenses for Commercialization. Buyer shall solely be responsible for all commercialization
activities for Patent Assets assigned by Seller as well as costs and expenses regarding the Patent Assets, including any governmental
assignment procedure, and on-going prosecution and maintenance costs thereof. Buyer shall have sole responsibility for selection
of counsel and other supporting consultants and resources for such commercialization activities.

 

		3.8	Audit. Buyer shall keep detailed and accurate records with respect to the accounting under
Section 3 of this Agreement in order to enable Seller to verify that it has received the proper payment due under Section 3 hereof.
Buyer shall retain such records for at least five (5) years from the date of any payment made by Buyer to Seller under this Agreement.
Once annually, Seller shall have the right through the use of independent certified accountants to make an audit during normal
business hours, of such records. Buyer shall promptly correct any errors or omissions disclosed by such audit and shall promptly
pay amounts determined to be owed, if any. Seller shall be responsible for all its costs of any such audit unless such audit reveals
an underpayment by Buyer of at least five percent (5%) for the audited period. In the event of such underpayment, Buyer shall reimburse
Seller for the cost of the audit.

 

 

SECTION 4

TERMS AND TERMINATION

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	11

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		4.1	Term. Unless earlier terminated in accordance with the terms and conditions of this Agreement,
this Agreement and the rights and obligations granted herein will continue in effect from the Effective Date until fifteen (15)
years after the last expiration date of the Patent Assets.

 

		4.2	Termination and *of Patent Assets.In
the event the Guaranteed Payments of each * (*)* (*) and * (*) * are not paid by
Buyer by their respective Guaranteed Payment Dates under this Agreement, and Buyer fails to cure the payment of a particular unpaid
Guaranteed Payment of such * by * of the next * (hereinafter referred to as a “Trigger Date”), Seller shall
have an option to terminate this Agreement and * the Patent Assets owned by Buyer (subject to the rights which Buyer has already
granted to any Settled Third Party as defined in Section 4.3 (a) below) at a “*”. In no event, shall the “*”
for * the Patent Assets be * than the * of (i) * (*)* US Dollars, or (ii) the total accrued payments of *, *, and * paid by Buyer
up to the date when Seller exercises the option set forth in this Section 4.2 hereof. Notwithstanding the foregoing, if Buyer
becomes a public company with a NASDAQ listing and the market capitalization of Buyer exceeds the amount of unpaid and due * which
have triggered Seller’s option to terminate this Agreement and * the Patent Assets by the Trigger Date, Seller may not exercise
its option to terminate this Agreement and * Patent Assets. Further, if Buyer’s total accrued payments of *, *, and * paid
to Seller by the Trigger Date set forth in this Section 4.2 hereof exceeds * (*)* US Dollars, Seller has no further option to
terminate this Agreement and * the Patent Assets.

			

 

		4.3	Effect of Termination.

		(a)	If Seller exercises its option to terminate this Agreement
and * the Patent Assets under Section 4.2 hereof, Seller will grant Buyer a * to any *that has already * with Buyer * to the Patent
Assets * (hereinafter, such * shall be referred to as a “*”), and Buyer shall pay to Seller any amount
of Net Revenue Share (including the future Net Revenue Share which will be obtained after the termination date) for amounts which
Buyer had settled or agreed with, and received from, such Settled Third Party.

 

		(b)	Within sixty (60) days after the date of termination,
Buyer shall render a report and pay all accrued amounts owing under Section 3 of this Agreement to Seller. For the avoidance of
doubt, Buyer shall continue to pay to Seller any amount of Net Revenue Share (including the future Net Revenue Share which will
be obtained after the termination date) which Buyer has settled or agreed with any Settled Third Party with respect to Buyer’s
commercialization activities on or before the termination date of this Agreement.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	12

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		(c)	Seller shall retain the right to conduct a post-termination
audit in accordance with Section 3.8 hereof, and Buyer shall retain books and records as required until after such audit and any
subsequent dispute arising from such audit.

 

		4.4	Survival Terms.Upon termination of this
Agreement for any reason, Section 1 (DEFINITIONS), Section 2.5 (Grant-Back), Section 3 (CONSIDERATION), Section 4.3 (Effect of
Termination), Section 5 (REPRESENTATION AND WARRANTIES OF SELLER), Section 6 (REPRESENTATION AND WARRANTIES OF BUYER), Section
8.1 (Patent Licensing and Assertions), Section 8.3 (Continuation of Encumbrances/Prior Licenses), Section 8.4 (Continuation of
Grant-Back relating to Subsequent Transfer), and Section 9 (MISCELLANEOUS) shall survive.

 

 

SECTION 5

REPRESENTATION AND WARRANTIES OF SELLER

 

Seller hereby represents
and warrants to Buyer as of the Effective Date as follows:

 

		5.1	Corporate Organization. Seller is a corporation duly organized, validly existing and in
good standing under the respective laws of its jurisdiction of incorporation, is duly qualified and is in good standing under the
laws of each jurisdiction in which the character of the properties and assets now owned or held by it or the nature of the business
now conducted by it requires it to be so licensed or qualified. Seller has full corporate power and authority to carry on its business
as now being conducted.

 

		5.2	Authority. Seller has full corporate power and authority to execute and deliver this Agreement
and to perform its obligations hereunder. The execution and delivery of this Agreement by Seller and the performance by Seller
of its obligations hereunder have been duly authorized by all necessary corporate action. This Agreement has been duly executed
and delivered by Seller and constitutes the legal, valid and binding obligation of Seller, enforceable against it in accordance
with its terms, subject to applicable laws affecting creditors’ rights generally and, as to enforcement, to general principles
of equity, regardless of whether applied in a proceeding at law or in equity.

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	13

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		5.3	No Conflict. The execution and delivery of this Agreement and the performance of the obligations
of Seller hereunder will not violate or be in conflict with any provision of law, any order, rule or regulation of any court or
other agency of government, or any provision of Seller’s articles of incorporation or bylaws. No consent, approval or authorization
of or declaration or filing with any Governmental Entity or other person or entity on the part of Seller is required in connection
with the execution or delivery of this Agreement or the consummation of the transactions contemplated hereby.

 

		5.4	Title. Seller has good and marketable title to the Patent Assets, including all rights,
title, and interest in the Patent Assets and the right to sue for past, present, or future infringement thereof. Seller has obtained
and properly recorded previously executed assignments for the Patent Assets as necessary or desirable to fully perfect its rights
and title therein in accordance with or as permitted by the law of any applicable country.

 

		5.5	As of the Effective Date, to the knowledge of Seller, there has been no litigation or suit filed
and/or pending, or written assertion by a third party, (i) by or against Seller concerning the ownership, validity, registrability,
enforceability, infringement or use of any Patent Assets, or (ii) contesting or challenging the ownership, validity, registrability
or enforceability of Seller’s right to use any Patent Assets. As of the Effective Date, to the knowledge of Seller, none
of the Patent Assets has ever been found invalid, unpatentable, or unenforceable for any reason in any third party-initiated administrative,
arbitration, judicial or other proceeding. As of the Effective Date, to the knowledge of Seller, none of the Patent Assets has
been or is currently involved in any reexamination, reissue, interpartes review, interference proceeding, or any similar proceeding
except as noted in Appendix C, and no such proceedings are pending or threatened. Seller has not improperly paid any “small
entity” fees to the United States Patent and Trademark Office for any Patent Assets.

 

		5.6	Seller also represents to Buyer that based only on a good faith search of Seller’s corporate
patent licensing database using the list of entity names set forth in Appendix D, neither Seller nor any of its Affiliates,
as of the Effective Date, has executed a patent license or patent non-assertion agreement with any of the entities identified in
Appendix D under which Seller expressly granted a license or covenant not to sue under the Patent Assets to such entities.
For clarity, this representation does not apply to any license or covenant not to sue (i) that arises by operation of law or equity,
by implication, through exhaustion, or based on similar legal theories, (ii) to any entity in its capacity as a direct or indirect
customer or supplier of a third party (including any customer or supplier of a third party) to which Seller or any of its Affiliates
has expressly granted a license or covenant not to sue, (iii) based on the sale or other transfer of products or services (including
the sale or other transfer of products or services by a third party to which Seller or any of its Affiliates has expressly granted
a license or covenant not to sue), (iv) granted by or through a third party, including but not limited to grants from or through
a standards setting organization, supplier or customer, or other third party, or (v) based on or associated with development, services
or technology license agreements.

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	14

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		5.7	Warranty Disclaimer. EXCEPT AS OTHERWISE PROVIDED HEREIN, SELLER MAKES NO REPRESENTATION
OR WARRANTY, EXPRESS OR IMPLIED, REGARDING THE PATENT ASSETS AND PATENT ASSETS ARE SOLD ON A STRICTLY “AS IS” BASIS.
FOR THE AVOIDANCE OF DOUBT, SELLER MAKES NO WARRANTY OR REPRESENTATIONS OF (i) MERCHANTABILITY OR FINTESS FOR A PARTICULAR PURPOSE,
OR (ii) REGARDING THE VALIDITY AND ENFORCEABILITY OF PATENT ASSETS. SELLER MAKES NO OTHER REPRESENTATIONS, WARRANTIES, OR COVENANTS,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY REPRESENTATION, WARRANTY, OR COVENANT THAT THE PRACTICE OF ANY INVENTION CLAIMED
IN AN PATENT ASSETS WILL NOT INFRINGE ANY OTHER PATENT THAT IS OR WAS AT THE TIME OWNED BY SELLER, NOR SHALL SELLER HAVE ANY LIABILITY
WITH RESPECT TO INFRINGEMENT BY BUYER OF PATENTS OR OTHER RIGHTS OF THIRD PARTIES.

 

 

SECTION 6

REPRESENTATION AND WARRANTIES OF BUYER

 

Buyer hereby represents
and warrants to Seller as of the Effective Date as follows:

 

		6.1	Corporate Organization. Buyer is a corporation duly organized, validly existing and, to
the extent applicable, in good standing under its respective laws of its incorporation, is duly qualified and, to the extent applicable,
is in good standing under the laws of each jurisdiction in which the character of the properties and assets now owned or held by
it or the nature of the business now conducted by it requires it to be so licensed or qualified. Buyer has full corporate power
and authority to carry on its business as now being conducted.

 

 

*Please note parts of this Agreement are designated with an asterisk which indicates that material has
been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

 

    	15

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		6.2	Authority. Buyer has full corporate power and authority to execute and deliver this Agreement
and to perform its obligations hereunder. The execution and delivery of this Agreement by Buyer and the performance by Buyer of
its obligations hereunder have been duly authorized by all necessary corporate action. This Agreement has been duly executed and
delivered by Buyer and constitutes the legal, valid and binding obligation of Buyer, enforceable against it in accordance with
its terms, subject to applicable laws affecting creditors’ rights generally and, as to enforcement, to general principles
of equity, regardless of whether applied in a proceeding at law or in equity.

 

		6.3	No Conflict. The execution and delivery of this Agreement and the performance of the obligations
of Buyer hereunder will not violate or be in conflict with any provision of law, any order, rule or regulation of any Governmental
Entity, or any provision of Buyer’s certificate of incorporation or bylaws. No consent, approval or authorization of or declaration
or filing with any Governmental Entity or other person or entity on the part of Buyer is required in connection with the execution
or delivery of this Agreement or the consummation of the transactions contemplated hereby.

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	16

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

SECTION 7

OTHER COVENANTS OF SELLER

 

		7.1	Cooperation; No Future Responsibility. Seller shall have no responsibility for any action
or proceeding relating to any of the Patent Assets which is commenced on or after the Effective Date (other than an action or proceedings
relating to a breach of this Agreement). However, for any applications or proceedings relating to the Patent Assets, including
pending, issued and lapsed Patent Assets that are reasonably revivable as of the Effective Date, Seller agrees to use all reasonable
efforts to cooperate with Buyer in (i) prosecuting such pending applications or proceedings, (ii) maintaining as granted such issued
patents, and (iii) reviving lapsed Patent Assets within available time periods for paying previously due payment of routine fees,
at the expense of Buyer, provided all such expenses will be reasonable and will be submitted to Buyer for pre-approval in writing.
Additionally, Seller agrees to pay any expenses related to registration and obtaining the patent right for Patent Assets (e.g.
registration fee), maintenance fees, and/or annuity fees payable and/or due up to and including the Effective date and through
sixty (60) days beyond the Effective Date; and Buyer agrees to reimburse Seller for all such fees paid by Seller after the Effective
Date for fees that are first due after the Effective Date. Such cooperation includes signing lawful papers and performing other
lawful acts which Buyer may request to further the prosecution of any of such pending applications or proceedings. Within six (6)
months after the Payment Date, Seller will provide all material and documents related to prosecution of the Patent Assets which
are in the actual possession of Seller and/or its external counsels and attorneys, including but not limited to all file histories
of all cases of the Patent Assets, including any interim but now-abandoned, lapsed or otherwise superseded applications or patents.
Buyer and Seller agree to discuss the appropriate handling of costs of transfer of actual case files. Seller also has already provided
and/or will provide within six (6) months after the Payment Date, declarations to standards bodies, existing claim charts, and
available technical reports relating to the Patent Assets.

 

 

		7.2	Further Cooperation. Upon Buyer’s request, with reasonable notice given, and without
additional consideration, Seller shall execute any further papers and documents and do such other acts as may be necessary and
proper to vest full title in and to the Patent Assets in Buyer, provided that all costs, including but not limited to attorneys’
fees, translation fees and patent office fees in any jurisdiction, shall be borne by Buyer. Seller shall assist Buyer, and any
successor, in every proper way to secure Buyer’s rights in the Patent Assets in any and all countries, including the disclosure
to Buyer of all pertinent information and data with respect thereto (including prior to Payment Date a) the contact information
for the patent attorney’s office used by Seller as of the Effective Date for each Patent Assets used for each Patent Asset
in each country, and b) a complete docket list of all pending cases, upcoming required responses to office actions and any required
fees), the execution of all applications, specifications, oaths, assignments and all other instruments which Buyer shall reasonably
deem necessary in order to apply for and obtain such rights and in order to assign and convey to Buyer, its successors, assigns,
and nominees the sole and exclusive right, title and interest in and to the Patent Assets, provided that all costs, including but
not limited to attorneys’ fees, translation fees and patent office fees in any jurisdiction, shall be borne by Buyer.

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	17

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

SECTION 8

OTHER COVENANTS OF BUYER

 

		8.1	Patent Licensing and Assertions. Buyer agrees that it shall use its commercially reasonable
efforts to minimize any participation by Seller in any activities relating to Buyer’s defense, enforcement or licensing of
any Patent Assets, except as otherwise provided in this Agreement. Buyer, on behalf of itself, its Affiliates, and their successors
and assigns, shall reimburse Seller for Seller’s reasonable costs and expenses (including employee time and attorney’s
fees) arising from any such participation actually required of Seller. This reimbursement does not extend to any other costs or
damages of any kind. It is Buyer’s general intent that in its commercial activities for licensing the Patent Assets, Buyer
will use reasonable efforts, under Buyer’s sound judgment, to generally attempt to first
negotiate with such potential licensees or potential purchasers prior to commencing any engaged legal action against such potential
licensees or purchasers.

 

		8.2	Fees and Other Actions.

		(a)	Any cost of any patent office proceedings taken on
and after Effective Date by Buyer, and any and all other costs regarding the Patent Assets and the cost of recording the transfer
of the Patent Assets, including any maintenance fees, annuities, renewal fees, issue fees and the like that first become due after
the Effective Date on the Patent Assets shall be borne solely by Buyer. Buyer shall reimburse Seller for any maintenance
fees, annuities and other patent office fees, if any, that first become due for any of the Patent Assets after the Effective Date
and are paid by Seller.

 

		(b)	Buyer after the Effective Date may elect to abandon
any pending application or issued patent that is part of the Patent Assets. Should Buyer elect to abandon any such application
or patent subject to the Encumbrances/Prior Licenses of Section 8.3 (c), however, it shall give reasonable notice to Seller of
its intention to do so at least sixty (60) days before the final deadline for the payment of any maintenance or other fee, or
the submission of any office action or other communication to the any patent office that would have the effect of such abandonment.

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	18

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		8.3	Continuation of Encumbrances/Prior Licenses.

		(a)	Buyer, on behalf of itself, its Affiliates, and their
successors and assigns, acknowledges and covenants that Buyer’s acquisition of the entire right, title, and interest in
and to the Patent Assets pursuant to this Agreement is subject to any and all existing encumbrances, outstanding issues, options
to acquire licenses, or any requirements imposed on Seller under agreements executed between Seller and any third party prior
to Effective Date of this Agreement (hereinafter, referred to as “Encumbrances/Prior Licenses”), all of which
shall run with the Patent Assets and shall remain in full force and effect in accordance with their terms in effect as of the
Effective Date. Buyer shall require that any assignees, exclusive licensees, and other successors to any interests in the Patent
Assets respect and comply with, and not interfere with, the Encumbrances/Prior Licenses and the terms hereof. For the avoidance
of doubt, Encumbrances/Prior License includes any requirements imposed by SSO, or the like. Buyer, on behalf of itself and all
of its direct and indirect successors and assigns, acknowledge and agrees that the Patent Assets are assigned subject to any and
all SSO Commitments, and Buyer shall ensure that the Patent Assets (including any assignments, exclusive licenses, or other transfer
of interest made by Buyer with respect to Patent Assets) are and remain subject to any and all SSO Commitments to the extent that,
as of the Effective Date, Seller has made such SSO Commitments. Buyer, for itself, its Affiliates, and its and their successors
and assigns, agrees not to challenge the validity and enforceability of such Encumbrances/Prior Licenses on the grounds that Buyer,
its Affiliates, or its or their successors or assigns had no notice of or were otherwise unaware of such Encumbrances/Prior Licenses.

 

		(b)	Without limitation of the generality of this Section
8.3 (a), Seller hereby notifies Buyer, in accordance with the *, between * (as successor to *) (“*”),
one of Seller’s Affiliates, and *, as amended (hereinafter referred to as “*”), that certain of
the Patent Assets are subject to a * under the *. Buyer acknowledges and agrees that the Patent Assets (together with all future
divisions, reissues, renewals, continuations, and continuations in part of the Patent Assets, if any, owned by Buyer or which
Buyer has the right to license) remain subject to, and Buyer is bound by, the following provisions (excerpts of which provisions,
and the definitions of certain related capitalized terms, are set forth in the attached Appendix E): (i) the * against
*and * in clause (a) of Section 8.1.1.1 and in Section 8.1.2 of the *, (ii) the obligations to *and * to * or * in Sections 8.1.1.2
and 8.1.1.4 through 8.1.8 of the * (subject to the terms set forth in Section 4.4 of the related *), and (iii) the terms of Section
8.3.1 of the *, with respect to such Patent Assets (including all future *, *, *, *, and * in part thereof, if any, owned by Buyer
or which Buyer has the *), as if the name of Buyer were substituted for * throughout Section 8 of the * (including Sections 8.1.4,
8.1.5, 8.1.6, 8.1.7, and 8.1.8) and as if all references to * meant, instead, Buyer and each Person Controlling, Controlled by,
or under common Control with Buyer (but, in each case, solely with respect to such Patent Assets and all future divisions, reissues,
renewals continuations, and continuations in part thereof, if any, owned by Buyer or which Buyer has the right to license).

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	19

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		(c)	Without limitation of the generality of Section 8.3
(a), Seller hereby notifies Buyer that certain of the Patent Assets (listed in Appendix F) are subject to a patent licensing
pool administered by SiproLAB Telecom (“SiproLAB Patents”), and have been already licensed (“SiproLAB
License(s)”) to certain licensees (“Prior SiproLAB Licensees”). Buyer acknowledges and agrees that
the SiproLAB Patents (together with all future divisions, reissues, renewals, continuations and continuation in part of the SiproLAB
Patents, if any, owned by Buyer or which Buyer has the right to license) remain subject to, and Buyer is bound by, such Prior
SiproLAB Licenses including any renewal term thereof.

 

		(d)	Without limitation of the generality of Section 8.3
(a), Seller hereby notifies Buyer, that certain of the Patent Assets may be subject to existing licenses (“Prior Renewable
Licenses”), whereby the licensees for such Prior Renewable Licenses (“Renewing Licensees”) have the
right to renew their Prior Renewable License and retain rights to the applicable patents, even after sale by Seller to Buyer.
Buyer acknowledges and agrees that the such applicable patents (together with all future divisions, reissues, renewals, continuations,
and continuations of such applicable Patents, if any, owned by Buyer or which Buyer has the right to license) remain subject to,
and Buyer is bound by, such Prior Renewable Licenses, in particular Seller’s obligation to provide future renewals of such
licenses to such applicable Patents to such Renewing Licensees, as governed by each such Prior Renewable License in existence
as of the Effective Date, if any.

 

		(e)	At Seller’s request, Buyer shall execute any
documents and instruments, and take any lawful actions, that, in each case, may be reasonably necessary to record or perfect the
reserved rights of Seller and its Affiliates and any licensees or other beneficiaries of the Encumbrances/Prior Licenses. Any
acts undertaken by Buyer solely under this Section 8.3 (e) shall be at Seller’s expense.

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	20

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		8.4	Continuation of Grant-Back relating to Subsequent Transfer. Buyer may sell, assign, transfer,
convey, enforce, license, and/or otherwise exploit its right, title or interest in and to the Patent Assets subject to Buyer’s
obligations set forth in this Agreement, including any Encumbrances/Prior Licenses described in Section 8.3 hereof. In no event
may Buyer sell, assign, transfer and/or convey any right, title or interest in and to the Patent Assets to any third party except
as provided in this Section 8.4. Any rights in the Patent Assets assigned by Buyer to its successors, assigns or exclusive licensees
(collectively, the “Transferees”) after the Effective Date of this Agreement, whether by sale, license, assignment
or other instrument, shall be by their express terms subject to (a) any Encumbrances/Prior Licenses described in Section 8.3, and
(b) the Grant-Back and reservation of rights to royalties under Section 2.5 (collectively, the Encumbrances/Prior Licenses and
the Grant-Back, “Continuing Licenses”). Buyer agrees and covenants that (i) the Grant-Back shall be binding
on any successors, assigns, or purchasers of Buyer, and/or of the Patent Assets (including any successors or assigns or subsequent
purchasers of Transferees), (ii) any successors, assigns, or purchasers of Buyer and/or of the Patent Assets (including any successors
or assigns or subsequent purchasers of Transferees) shall assume in writing all rights and obligations of Buyer under this Agreement,
and (iii) the Continuing Licenses in accordance with their terms. Buyer further agrees to ensure that Seller and its Affiliates
are designated as third party beneficiaries with respect to said obligations (including the Continuing Licenses) in all subsequent
transfers of rights and assignments affecting any Patent Assets.

 

 

 

SECTION 9

MISCELLANEOUS

 

		9.1	Confidential Information. The Parties consider the terms of this Agreement to be strictly
confidential. Neither Party shall disclose the terms of this Agreement to any third Person (excluding the Affiliate of a Party)
except: (i) to legal counsel; (ii) to auditors; (iii) to the extent, if any, required by law; (iv) in accordance with the terms
of a protective order duly entered in a legal or administrative proceeding; (v) as required by any Governmental Entity; or (vi)
contractors and/or investors under a non-disclosure agreement with terms of similar in scope to this Section 9.1; or (vii) with
the prior written consent of Buyer and Seller (such consent not to be unreasonably withheld); provided, however that Buyer may
publicly file, in its sole discretion, Appendix B or any other instrument of transfer of the Patent Assets with relevant
Governmental Entities and for the purpose of enforcing this Agreement. For the avoidance of doubt, the existence and terms of the
Encumbrances/Prior Licenses shall be deemed confidential information of Seller and shall not be used or disclosed to third parties
by Buyer, other than to its own legal counsel and contractors as provided above, for any purpose whatsoever. If a Party is required
to disclose this Agreement or the terms hereof pursuant to a subpoena or other legal mandate, it shall immediately give the other
Party notice thereof and cooperate with such other Party in contesting or limiting such subpoena or legal mandate. The Party shall
not advertise, publish, or disclose the existence of this Agreement without the prior consent of the other Party. Such consent
would not be unreasonably withheld. In addition, the Parties also be bound by the MUTUAL NON-DISCLOSURE AGREEMENT having an effective
date of January 24, 2013 and have also entered into a written COMMON INTEREST AGREEMENT having an effective date of the Effective
Date.

 

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	21

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		9.2	Limitation of Liability. TO THE FULL EXTENT PERMITTED BY APPLICABLE LAW AND IN NO EVENT
WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL PUNITIVE, MORAL, OR CONSEQUENTIAL DAMAGES WHATSOEVER PURSUANT TO OR
OTHERWISE IN CONNECTION WITH THIS AGREEMENT, WHETHER ARISING IN CONTRACT, TORT (INCLUDING, WITHOUT LIMITATION AND FOR THE AVOIDANCE
OF DOUBT, NEGLIGENCE OR BREACH OF STATUTORY DUTY), WARRANTY, OR OTHERWISE, EVEN IF IT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION WILL APPLY EVEN IF THE REMEDIES PROVIDED FOR IN THE AGREEMENT COMPLETELY FAIL
OF THEIR ESSENTIAL PURPOSE.

 

		9.3	Notices. All notices under this Agreement shall be in writing, specifically refer to this
Agreement, and be delivered in person or sent by international carrier or overnight mail, or by other means providing proof of
delivery, to the Parties at their respective addresses set forth below, or to any other address of which a Party notifies the other.
Other communications under this Agreement may be made by any of the foregoing means as well as electronic mail to an e-mail address
designated by a Party. All notices shall be deemed to be effective on the date of actual receipt or five days after transmission
as provided above, whichever is sooner.

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	22

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

	 	IF TO SELLER:	IF TO BUYER:
	 	
        Panasonic Corporation

        Intellectual Property Center
	
        Inventergy, Inc.

        19925 Stevens Creek Blvd

	 	2-1-61 Shiromi, Chuo-ku, Osaka City	Suite 100
	 	540-6208, Japan	Cupertino, CA 95014, USA
	 	
        Attention:

        General Manager, Licensing Group
	
        Attention: Joe Beyers

        Chairman & CEO

	 	Email: *	Email: joe@inventergy.com

 

		9.4	Assignment of this Agreement. Parties shall not assign this Agreement or any of its rights
or obligations hereunder, except to an Affiliate of the respective Party, without the prior written consent of the other Party,
and any other assignment or attempted assignment of this Agreement or any part thereof by a Party without the prior written consent
of the other Party shall be void. If Party intends to assign this Agreement or any of its rights or obligations hereunder to its
Affiliate, such Party shall provide a prior written notice to the other Party for such assignment not later than thirty (30) days
before the assignment date. This Agreement is binding upon and inures to the benefit of successors and permitted assigns of the
Parties. Except as expressly provided in this Agreement, for clarity, nothing in this Agreement shall in any way limit the sale,
transfer, licensing, or other exploitation of the Patent Assets by Buyer or any of Buyer’s successors or assigns or purchasers
of the Patent Assets.

 

		9.5	Drafted Jointly. Each of the Parties and their respective counsel has participated
in the negotiation and drafting of this Agreement, and have had an opportunity to review this Agreement. In the event that any
ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by all Parties
and no rule of construction, presumption or burden of proof shall arise favoring one Party concerning the interpretation of ambiguous
provisions or otherwise by virtue of one Party’s presumed authorship of this Agreement or any provision hereof.

 

		9.6	Entire Agreement, Amendment. This Agreement, including all attachments, constitutes the
complete and final agreement between the Parties, and supersedes all prior and contemporaneous negotiations and agreements between
the Parties concerning its subject matter. This Agreement may not be altered, modified or waived in whole or in part, except in
writing, signed by duly authorized representatives of the Parties. The interpretation of this Agreement may not be explained or
supplemented by any course of dealing or performance, or by usage of trade.

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	23

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		9.7	English Language. This Agreement is made in English and as such the original English version
of this Agreement shall prevail and govern any translation or retranslation. The titles and headings used in this Agreement are
intended as a convenience only, and shall not affect the interpretation of its provisions.

 

		9.8	Relationship of the Parties. The Parties are separate and independent legal entities. Nothing
in this Agreement shall constitute a partnership nor make either Party the agent or representative of the other. Neither Party
has the authority to bind the other or to incur any liability on behalf of the other, nor to direct the employees of the other.
Neither Party shall hold itself out contrary to the terms of this paragraph. Neither Party shall be liable for the representations,
acts, or omissions of the other Party contrary to the terms of this Agreement.

 

		9.9	Jurisdiction, Venue and Governing Law. This Agreement shall be governed by and construed
in accordance with the substantive laws, but not the choice of law rules, of the State of California and the applicable federal
laws of the United States.

 

		9.10	Dispute Resolution. The Parties shall make best efforts to settle amicably and promptly
by mutual consent of the Parties, any dispute, claim or controversy arising out of or relating to this Agreement or the breach,
enforcement, interpretation or validity thereof. If such dispute, claim or controversy cannot be settled between the Parties within
ninety (90) days after the occurrence of such dispute, claim or controversy, they shall be, at the request of either Party, finally
settled by binding arbitration before one arbitrator in Osaka, Japan pursuant to the Commercial Arbitration Rules of The Japan
Commercial Arbitration Association if Buyer requests the arbitration, or in San Francisco, California pursuant to the Commercial
Arbitration Rules of the American Arbitration Association if Seller requests the arbitration. The award rendered by the arbitration
arbitrator shall be final and binding upon both Parties. Judgment on the award may be entered in any court having jurisdiction.
This Section 9.10 shall not preclude parties from seeking provisional remedies in aid of arbitration from a court of appropriate
jurisdiction. If Seller prevails in any such arbitration for any damages of owed Guaranteed Payments or Net Revenue Share, Buyer
will pay and be responsible for all Seller’s reasonable attorneys’ fees and costs of arbitration.

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	24

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

		9.11	Severability. If any provision of this Agreement is found or held to be unenforceable or
invalid, the provision shall be severed and the remainder of this Agreement shall be valid and enforceable. The Parties shall negotiate
in good faith a substitute provision that most nearly affect the Parties’ intent.

 

		9.12	Waiver. No waiver of any term or condition of this Agreement, whether by conduct or otherwise,
in any one or more instances, shall be deemed to be a further or continuing waiver of that term or condition or a waiver of any
other term or condition.

 

		9.13	Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed to be an original, but all of which shall constitute on and the same agreement.

 

		9.14	No Use for Weapons. Buyer shall not practice the Patent Assets for Purpose Related to Weapons.
For the purpose of this Agreement, “Purpose Related to Weapons” means the design, development, manufacture or
use of any weapons, including without limitation, nuclear weapons, biological weapons, chemical weapons and missiles and land mines.

 

		9.15	Standstill Agreement. Seller agrees, until the Payment Date, not to solicit or encourage
inquiries or proposals, either directly or indirectly, furnish any information relating to or participate in any negotiations or
discussions concerning or enter in any transaction for any acquisition or purchase of any of the Patent Assets with any potential
buyers (this Section 9.15 termed as the “Standstill Agreement”). Seller agrees to cause its Affiliates, officers,
directors, employees, brokers, intermediaries and agents to conform to the terms of such Standstill Agreement.

 

[The remainder of this page has been
intentionally left blank. Signature page follows.]

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	25

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be executed in duplicate by its duly authorized representative.

 

	 	Panasonic Corporation	 	 	Inventergy,
    Inc.	 
	 	 	 	 	 	 
	By:	 	 	By:	 	 
		 	 	 	 	 
	 	(Signature)	 	 	(Signature)	 
	 	 	 	 	 	 
	Name:	Mamoru Yoshida	 	Name:	Joseph W. Beyers	 
	 	 	 	 	 	 
	Title:	Managing Director, Member of the Board	 	Title:	Chariman & CEO	 
	 	 	 	 	 	 
	Date:		 	Date:		 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	26

    	 

    

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

Appendix A - Appendix Patents

 

	Subtotal	101	 
	 	 	 
	Internal Family ID	Publication Number	Patent Status
	 	 	 
	Inv-01	US6726297	Granted
	Inv-03	US8009549	Granted
	Inv-04	US8416810	Granted
	Inv-08	US7646702	Granted
	Inv-08	US8238226	Granted
	Inv-09	US7593317	Granted
	Inv-15	US7929627	Granted
	Inv-16	US7826557	Granted
	Inv-21	US7792084	Granted
	Inv-23	US8064393	Granted
	Inv-26	US20120314645	Pending
	Inv-26	US8270332	Granted
	Pana-01	US6366763	Granted
	Pana-01	US6370359	Granted
	Pana-01	US6381445	Granted
	Pana-01	US6400929	Granted
	Pana-01	US6487394	Granted
	Pana-01	US6505035	Granted
	Pana-01	US6597894	Granted
	Pana-01	US6611676	Granted
	Pana-01	US6973289	Granted
	Pana-01	US7636551	Granted
	Pana-02	US6637001	Granted
	Pana-02	US20050002477	lapsed
	Pana-03	US6813323	Granted
	Pana-03	US20050219071	lapsed
	Pana-04	US6734810	Granted
	Pana-04	US6922159	Granted
	Pana-04	US6940428	Granted
	Pana-05	US6069884	Granted
	Pana-06	US6119004	Granted
	Pana-07	US6069924	Granted

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	27

    	 

    

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

	Pana-08	US20040048578	lapsed
	Pana-08	US6636723	Granted
	Pana-09	US6628630	Granted
	Pana-10	US6404778	Granted
	Pana-11	US6611509	Granted
	Pana-11	US6807162	Granted
	Pana-11	US6973065	Granted
	Pana-11	US7778224	Granted
	Pana-12	US6765894	Granted
	Pana-12	US7656844	Granted
	Pana-12	US8437316	Granted
	Pana-13	US6839335	Granted
	Pana-14	US7072416	Granted
	Pana-14	US7760815	Granted
	Pana-15	US6868056	Granted
	Pana-16	US6944208	Granted
	Pana-17	US6781973	Granted
	Pana-18	US7145886	Granted
	Pana-19	US6847828	Granted
	Pana-19	US7386321	Granted
	Pana-20	US7266118	Granted
	Pana-21	US7133379	Granted
	Pana-22	US6876870	Lapsed
	Pana-22	US7392019	Granted
	Pana-23	US7339949	Granted
	Pana-24	US7702025	Granted
	Pana-25	US7460502	Granted
	Pana-26	US7269774	Granted
	Pana-27	US7385934	Granted
	Pana-28	US7114121	Granted
	Pana-29	US7162206	Granted
	Pana-30	US7746762	Granted
	Pana-31	US7693140	Granted
	Pana-32	US20080020802	lapsed
	Pana-32	US7299027	Granted

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	28

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

	Pana-33	US20070255993	Pending
	Pana-33	US20120230257	lapsed
	Pana-33	US20120263250	lapsed
	Pana-33	US20120287775	lapsed
	Pana-34	US7251469	lapsed
	Pana-34	US7764711	Granted
	Pana-35	US20070254715	Pending
	Pana-35	US8086270	Granted
	Pana-36	US7848439	Granted
	Pana-37	US8175604	Granted
	Pana-38	US7860184	Granted
	Pana-39	US8073070	Granted
	Pana-40	US8249132	Granted
	Pana-41	US20090116434	Pending
	Pana-42	US8218681	Granted
	Pana-43	US8249178	Granted
	Pana-44	US5583851	Granted
	Pana-45	US5873027	Granted
	Pana-45	US6336040	Granted
	Pana-46	US5757870	Granted
	Pana-46	US5818869	Granted
	Pana-46	US7136367	lapsed
	Pana-47	US6175558	Granted
	Pana-47	US6301237	Granted
	Pana-47	US6529492	Granted
	Pana-47	US6370131	Granted
	Pana-47	US6584088	Granted
	Pana-47	US6549526	Granted
	Pana-47	USRE41444	Granted
	Pana-48	US6295301	Granted
	Pana-48	US6697384	Granted
	Pana-49	US20030007472	lapsed
	Pana-49	US6466563	Granted
	Pana-50	US7535864	Granted
	Pana-50	US6370134	Granted

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	29

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

	Pana-50	US7035233	Granted
	WCDMA (pool) 01	US5677929	lapsed
	WCDMA (pool) 01	USRE37420	Granted
	WCDMA (pool) 01	USRE39954	Granted
	WCDMA (pool) 01	US20030087644	lapsed
	WCDMA (pool) 01	US20060121930	lapsed
	WCDMA (pool) 01	US20080261545	lapsed
	WCDMA (pool) 07	US6738646	Granted
	WCDMA (pool) 07	US7460880	Granted
	WCDMA (pool) 07	US7761113	Granted
	WCDMA (pool) 09	US6760590	Granted
	WCDMA (pool) 09	US6799053	Granted
	WCDMA (pool) 09	US7206587	Granted

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	30

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

Appendix B – Transfer Documents

 

Panasonic Corporation,
a Japanese corporation having its principal place of business at 1006, Oaza Kadoma, Kadoma-shi, Osaka 571-8501, Japan (“Assignor”),
hereby irrevocably assigns to Inventergy, Inc., a Delaware corporation with a business address at 19925 Stevens Creek Boulevard,
Suite 100, Cupertino, California 95014, USA (“Assignee”), as of the date set forth below, the entire Assignor’s
right, title, and interest in and to (a) all US patents as listed in Appendix A (“Appendix Patents”),
and (b) all of their related families, including all counterpart patents and applications in any geography or jurisdiction, pending
applications and lapsed or otherwise abandoned patents or patent applications which: (i) claim priority to the Appendix Patents,
(ii) to which the Appendix Patents claimed priority (“Priority Patents”), or (iii) which claim priority to the
Priority Patents (collectively, (a) and (b) are the “Patent Assets”), and any patents or patent applications
subject to any terminal disclaimer with regard to such patents and/or patent applications, and all causes of action, rights, and
remedies arising under any such Patent Assets prior to, on or after the Effective Date of this Agreement and all claims for damages
by reason of past, present or future infringement or other unauthorized use of such Patent Assets with the right to sue for and
collect such damages.

 

Assignor also hereby
authorizes the respective patent office of governmental agency in each jurisdiction to issue any and all patents or certificates
of invention which may be granted upon any of the Patent Assets in the name of Assignee, as the assignee to the entire interest
therein.

 

The terms and conditions
of this assignment shall inure to the benefit of Assignee, its successors, assigns, and other legal representatives, and shall
be binding upon Assignor, its successors, assigns, and other legal representatives.

 

IN WITNESS WHEREOF,
Assignor have caused their duly authorized representatives to execute this Assignment.

 

ASSIGNOR

Panasonic Corporation

 

	By:	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 
	 	 	 
	Date:	 	 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	31

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

 

Appendix C – List of Patents

 

	Subtotal	3	 
	 	 	 
	Internal Family ID	Publication Number	Patent Status
	 	 	 
	Pana-47	USRE41444	Granted
	WCDMA (pool) 01	USRE37420	Granted
	WCDMA (pool) 01	USRE39954	Granted

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	32

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

Appendix D – List of Entity Names

 

	Category	Company Name 
	*	*
	 	*
	 	*
	*	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	*	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	*	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*
	 	*

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	33

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	34

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

 

Appendix E –

 

*

 

 

 

 

 

 

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

    	35

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED

 

Appendix F – SiproLAB Patents

 

Any Patent Assets listed in the website
of SiproLAB Telecom now available at: [http://www.sipro.com/LicensedPatents-W-CDMA.html]

 

* The URL
of the website listing SiproLAB Patents stated above may be changed from time to time.

 

 

 

 

*Please note parts of this Agreement are designated
with an asterisk which indicates that material has been omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

 

    	36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]